

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/042036 A2

(51) International Patent Classification⁷: C12N 1/16,
15/81, C07K 14/39

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/EP2003/012377

(22) International Filing Date:
6 November 2003 (06.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
102 52 245.6 7 November 2002 (07.11.2002) DE

(71) Applicant and

(72) Inventor: **PORRO, Danilo** [IT/IT]; Via Lodrona, 80, I-22036 Erba (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRANDUARDI, Paola** [IT/IT]; Via C. Mezzofanti, 14, I-20133 Mailand (IT). **VALLI, Minoska** [IT/IT]; Via Bolgare, 15, I-24050 Calcinate (IT). **ALBERGHINA, Lilia** [IT/IT]; Via Boscovich, 19, I-20124 Mailand (IT).

(74) Agents: **MAI, Peter** et al.; Industriepark Höchst Geb. F821, 65926 Frankfurt am Main (DE).

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/042036 A2

(54) Title: PROCESS FOR EXPRESSION AND SECRETION OF PROTEINS BY THE NON-CONVENTIONAL YEAST ZYGOSACCHAROMYCES BAILII

(57) Abstract: Herein is disclosed a method for the production of proteins. The protein is expressed by a yeast belonging to the species *Zygosaccharomyces bailii*. The yeast secretes the protein produced into the culture medium from where it is isolated, thereby simplifying the isolation process. Preferably the yeast is cultivated in chemically defined medium, thereby further simplifying the isolation process significantly.

PROCESS FOR EXPRESSION AND SECRETION OF PROTEINS BY THE
NON-CONVENTIONAL YEAST ZYGOSACCHAROMYCES BAILII

5 High level production of proteins from engineered organisms (recombinant, mutagenised, ...) provides an alternative to the extraction of the proteins from natural sources. Natural sources of proteins are often limited, and furthermore the concentration of the desired product is generally low so extraction is regularly very cost-intensive or even impossible. Besides, extraction might bear the danger
10 of toxic or infectious contamination depending on the natural origin of the protein.

With the advent of molecular cloning in the mid-70s, it became possible to produce foreign proteins in new hosts. Recombinant DNA (rDNA) technologies (genetic, protein and metabolic engineering) allow the production of a wide range of peptides and proteins from naturally-non producing cells. In fact the first
15 biotech-products on the world market made by means of rDNA were pharmaceutical products (for example insulin, interferons, erythropoietin, vaccine against hepatitis B) and industrial enzymes (for example used for the treatments of food, feed, detergents, paper-pulp and health care). World-sales of the top-20 recombinant pharmaceutical products in 2000 was about 13 billions Euro, while
20 the world-wide market for the industrial enzymes was about 2.0 and it is projected to reach about 8 billions Euro in 2008.

Microorganisms as well as cultured cells from higher organisms (such as mammals, insects or plants) represent the mainly conceivable hosts for the production of heterologous as well as homologous proteins.

25 Several processes using mammalian cell culture for the production of proteins have been developed and many in such a manner produced proteins are on the market. Among them, several vaccines, monoclonal antibodies, interferon, blood factors, urokinase and tPA, hormones and growth factors.

The main advantage of a mammalian cell based expression system is the ability of
30 mammalian cells to process the proteins in a proper way (correct folding, appropriate post-translational modification, correct glycosylation, specific proteolytic activities, etc.). A cloned protein expressed from recombinant DNA of mammalian origin (human) is usually correctly processed and folded and commonly secreted into the medium, allowing a fast recovery and purification.

35 On the other hand the costs of production are generally quite high due to a usually low level of expression, costs of the mammalian medium components, very slow growth rates and demanding culture conditions. Furthermore, production in mammalian cells bears the danger of toxic or infectious contamination of the product.

Microorganisms (prokaryotic as well as eukaryotic) are advantageous hosts for the production of proteins because of high growth rates and commonly ease of genetic manipulation. But, in particular, bacterial hosts lack the ability of a correct protein processing and in a lot of cases heterologously produced proteins build up inclusion bodies inside of the bacterial cells, whereupon the proteins are lost, because their enzymatic activity can in most instances not be reconstituted. Due to their incorrect structure any use of such proteins for the treatment of humans is also excluded.

Yeast hosts can combine the advantages of unicellular organisms (i.e., ease of genetic manipulation and growth) with the capability of a protein processing typical for eukaryotic organisms (i.e. protein folding, assembly and post-translational modifications), together with the absence of endotoxins as well as oncogenic or viral DNA. Starting from the early 80s, the majority of recombinant proteins produced in yeast have been expressed using *Saccharomyces cerevisiae* (Hitzeman, R. A. et al., 1981, Nature 293, 717-22). The choice was determined by the familiarity of molecular biologists to this yeast together with the accumulated knowledge about its genetics and physiology. Furthermore, *S. cerevisiae* is an organism generally regarded as safe (GRAS). However, this yeast is not an optimal host for the large-scale production of foreign proteins, especially due to its characteristics regarding fermentation needs. In particular, growth of *S. cerevisiae* shows a very pronounced Crabtree effect, therefore fed-batch fermentation is required to attain high-cell densities (see for example Porro, D., et al., 1991, Res. Microbiol. 142, 535-9). Furthermore, this yeast is comparatively sensitive regarding the culture conditions, for example regarding the pH value and the temperature. Therefore, its cultivation is complicated and requires a highly sophisticated equipment. In addition, the proteins produced by *S. cerevisiae* are often hyper-glycosylated and retention of the products within the periplasmic space is frequently observed (Reiser, J. et al., 1990, Adv. Biochem. Eng./Biophys. 43, 75-102 and Romanos, M. A. et al., 1992, Yeast 8, 423-88). Furthermore, due to the partial retention of the protein in *S. cerevisiae*, a fraction of the protein is commonly degraded. These respective degradation products are generally very difficult to remove from the desired product. Disadvantages such as these have promoted a search for alternative hosts, trying to exploit the great biodiversity existing among the yeasts, and starting the development of expression systems in the so-called "non conventional" yeasts. Prominent examples are *Hansenula polymorpha* (Buckholz, R. G. et al., 1991, Bio/Technology 9, 1067-72); *Pichia pastoris* (Fleer, R., 1992, Curr. Opin. Biotechnol. 3, 486-96); *Kluyveromyces*

lactis (Gellissen, G. et al., 1997, Gene 190, 87-97); *Yarrowia lipolytica* (Muller, S. et al., 1998, Yeast 14, 1267-83) among others. Another yeast genus under investigation is the genus *Zygosaccharomyces*. Eleven species, which appear to be evolutionary quite close to *S. cerevisiae* and not so far from *K. lactis* have been 5 classified so far (James, S. A. et al., 1994, Yeast 10, 871-81, Steels, H., et al., 1999, Int. J. Syst. Bacteriol. 49, 319-27 and Kurtzman, C. P., et al., 2001, FEMS Yeast research 1, 133-8). An exceptional resistance to several stresses renders some of the *Zygosaccharomyces* species potentially interesting for industrial 10 purposes. For example *Z. rouxii* is known to be salt tolerant (osmophilic) and *Z. bailii* is known to tolerate high sugar concentrations and acidic environments as well as relatively high temperatures of growth (Makdesi, A. K. et al. 1996, Int. J. Food Microbiol. 33, 169-81 and Sousa, M. J. et al., 1996, Appl. Environm. Microbiol. 62, 3152-7). However, the data available related to the molecular 15 biology of these yeasts are very poor. While expression and secretion of a heterologous protein could be achieved in *Z. rouxii* (Ogawa, Y. et al. 1990, Agric. Biol. Chem. 54, 2521-9), for *Z. bailii* just the first molecular tools to successfully transform this yeast and to express heterologous proteins intracellularly have been developed (WO 00/41477). Since purification of intracellular proteins is very elaborate, the use of this host for industrial production processes remains limited. 20 Furthermore, while a lot of such non-conventional yeasts show specific advantages regarding their cultivation requirements, a lot of times these advantages are foiled by unexpected negative characteristics or unsolvable problems in their handling. In a lot of instances the tools for transformation of the organisms or expression of heterologous genes are not developed or the 25 development fails due to unfavourable natural properties of the organism in question. The secretory capabilities often impose further problems for the production of proteins in industrial scale. If the organism does not allow the efficient secretion of the desired protein, the isolation of the product is significantly complicated. In addition, some very interesting products, such as 30 Interleukin 1- β , turned out to be toxic for the cells as long as they are intracellularly located (Fleer, R. et al., 1991, Gene 107, 285-95). Production of such proteins is therefore only possible if the host comprises a highly potent secretory system that can be exploited. Another problem come from a potentially different codon usage or codon frequency that can hamper the expression of 35 heterologous genes in such organisms decisively.

In consideration of the state of the art, the problem to be solved by the present invention was to provide a new, easy and economical method for the production

of proteins. Apart of being cost effective that method should be easy to perform and allow the production of highly pure proteins in a high yield.

This problem as well as all further not explicitly mentioned problems, that are easily deduced from the introductory explicated contents, are solved by the objects outlined in the claims of the instant invention.

An advantageous process for the production of a protein is provided by a method as outlined in claim one. This method comprises culturing a *Zygosaccharomyces bailii* strain expressing and secreting the protein and isolating the protein. This process is particularly advantageous in that *Z. bailii* can be cultured yieldingly in a chemically defined medium without the addition of complex ingredients that have to be separated tediously from the protein produced. Surprisingly, the secretory capacity of this yeast in chemically defined medium is significantly superior to the secretory capacity of *S. cerevisiae* under identical conditions. A further important advantage is the surprising fact that the protein produced by *Z. bailii* is not only readily secreted but also near to completion, what is not the case for *S. cerevisiae* under identical conditions. Through efficient secretion of the desired protein by *Z. bailii* also no degradation of the protein takes place. Subsequently, the purification of the product is significantly simplified.

Further major advantages of *Z. bailii* as host organism for protein production, and in particular for production of heterologous proteins are a naturally favourable codon usage as deduced from the examples presented herein and the comparatively low demands on the culture conditions. This is in particular due to a high acid and temperature tolerance as well as a weak Crabtree effect allowing the cultivation with a high sugar concentration from the beginning (i.e. batch instead of fed-batch cultivation) and the omission of extremely sophisticated regulations of the culture conditions such as temperature or pH. Accordingly, this method allows a cost effective production of proteins in an easy way even in industrial scale yielding proteins of high purity.

The term "expression" of a protein by a host cell is well known to the skilled artisan. Usually expression of a protein comprises transcription of a DNA sequence into a mRNA sequence followed by translation of the mRNA sequence into the protein. A more detailed description of the process can be found for example in Knippers, R. et al, 1990, Molekulare Genetik, Chapter 3, Georg Thieme Verlag, Stuttgart.

The term "secretion" of a protein as known in the art means translocation of the protein produced, from inside of the cell to outside of the cell, thereby

accumulating the protein in the culture medium. A more detailed description of the process can be found for example in Stryer, L., 1991, Biochemie, Chapter 31, Spektrum Akad. Verlag, Heidelberg, Berlin, New York.

The protein produced might be any protein known in the art for which an industrial production is desirable. For example the protein might be useful in the pharmaceutical field, such as medication or vaccine or in pre-clinical or clinical trials among others (examples are growth hormones, tissue plasminogen activator, hepatitis B vaccine, interferones, erythropoietin). The protein produced might also be useful in industry for example in the area of food production (e.g. 5 β -galactosidase, chymosin, amylases, glucoamylase, amylo-glucosidase, invertase) or textile and paper production (proteases, amylases, cellulases, lipases, catalases, etc.). Enzymes are useful among others as detergents (proteases, lipases and surfactants) and their characteristics of stereo-specificity are furthermore 10 exploitable in a wide number of bioconversions, yielding a desired chiral compound. Another promising application of recombinant enzymes that can be 15 produced by the method of the instant invention is the development of biosensors.

The proteins secreted can vary greatly in size (molecular weight). The herein described method functions well for very small proteins (e. g. IL-1 β , 17 kDa, see 20 Fig. 5), but also for quite large proteins (e.g. GAA, 67.5 kDa, see Fig. 8a). The secreted proteins may or may not comprise consensus sites for glycosylation. Such consensus sites might occur naturally or might be introduced by genetic engineering. Depending on the intended use of the protein produced it might also be advantageous to remove naturally occurring consensus sites for glycosylation 25 by genetic engineering, thereby preventing for example hyper-glycosylation of the protein. Remarkably, the herein described method leads to proteins that conserve their desired catalytic characteristics after the secretion (e.g. GAA, see Fig. 8a).

In one embodiment of the present invention the *Z. bailii* strain is transformed with a vector comprising a DNA sequence coding for the protein, functionally linked to a signal sequence leading to the secretion of the protein and further functionally 30 linked to a promoter leading to the expression of the protein.

The term "vector" refers to any agent as such a plasmid, cosmid, virus, phage, or linear or circular single-stranded or double-stranded DNA or RNA molecule, derived from any source that carries nucleic acid sequences into a host cell. Preferably a vector is capable of genomic integration or autonomous replication. 35 Such a vector is capable of introducing a 5' regulatory sequence or promoter region and a DNA sequence for a selected gene product into a cell in such a

manner that the DNA sequence is transcribed into a functional mRNA, which may or may not be translated and therefore expressed. Preferably the vector is an extra-chromosomal plasmid. Such a plasmid comprises preferably an autonomously replicating sequence (ARS) and advantageously a centromeric sequence (CEN) in addition. More preferable the plasmid is a 2μ -like episomal multicopy plasmid. Even more preferably the plasmid is derived from an endogenous episomal plasmid from a *Z. bailii* strain such as pSB2 (Utatsu, I. et al., 1987, J. Bacteriol. 169, 5537-45) and more preferably from pZB₁ or pZB₅ (see Fig. 9).

The plasmid pZB₅ was extracted from NCYC 1427 and partially sequenced. Accordingly, the plasmid comprises preferably at least 35, more preferably at least 55 and even more preferably at least 75 and even more preferably at least 100 bases from at least one of the sequences selected from the list of SEQ ID No.: 63, SEQ ID No.: 64, SEQ ID No.: 65, SEQ ID No.: 66, SEQ ID No.: 67, SEQ ID No.: 68, SEQ ID No.: 69, SEQ ID No.: 70 or SEQ ID No.: 71.

Yeast multicopy plasmids (also referred to as 2μ or $2\mu\text{m}$ -like plasmids) isolated from different yeast genus or species usually show a well conserved structural homology while having a low sequence homology. Some regulatory elements were identified as necessary and sufficient to build a functional multicopy plasmid. These are:

the recombinase promoting amplification of these plasmids, encoded by the *FLP* gene. (Blanc H., et al., 1979, Mol. Gen. Genet. 176, 335-42 and Broach J.R. et al., 1980, Cell 21, 501-8);

two inverted repeats (IR-sequences);
a single origin of replication (ARS) at the junction between an internal repeat and a unique region of the plasmid (Broach J. R. et al., 1980, Cell 21, 501-8; Brewer B. J. et al., 1987, Cell 51, 463-71; McNeil J. B., et al., 1980, Curr. Genet. 2, 17-25) and

the regulatory proteins *REP1/REP2* (in *Z. bailii* referred to as *TFB/TFC*), controlling the amplification process, by limiting the recombinase activity in the cell through-mediated repression of *FLP* gene expression (Broach J. R. et al., 1980, Cell 21, 501-8; Jayaram M. et al., 1983, Cell 34, 95-104).

Within the scope of the instant invention these key elements of the 2μ plasmid are preferably derived from *Z. bailii*, even more preferably from *Z. bailii* NCYC1427 or ATCC36947. Particularly preferred these sequences correspond to SEQ ID No.: 71 (IR-ARS), SEQ ID No.: 72 (*FLP*), SEQ ID No.: 74 (*TFB*) and SEQ ID No.: 76

(*TFC*), respectively. The expressed recombinase and the expressed regulatory proteins exhibit preferably the amino acid sequence shown in SEQ ID No.: 73 (*FLP*), SEQ ID No.: 75 (*TFB*) and SEQ ID No.: 77 (*TFC*), respectively. Preferably the plasmid additionally comprises the homologue upstream regions of the *FLP* and the *TFB/TFC* genes, in order to obtain an optimal control of the transcription level.

Generally speaking the plasmid preferably comprises sequences for (autonomous) replication, stabilization and/or plasmid copy number control, obtainable from a *Z. bailii* strain.

10 Preferably the plasmid is pEZ₁ (see Fig. 9c)

Particularly preferred is the plasmid pEZ₂ (see Fig. 9d). One preferred way to construct pEZ₂ is to amplify the IR/ARS region and the TFC/FLP genes including their homologous promoters by PCR with the oligos

5'-AGAATCAATCATTAGTGTGGCAGGAG-3' (SEQ ID NO.: 90) and

15 5'-TAAAAAACTGCCGCCATATTCGTC-3' (SEQ ID NO.: 91, *IRAARS*),

5'-AGAATGAACTCAGAGTTCTCTCTTG-3' (SEQ ID NO.: 86) and

5'-CCTATGTCCGAGTTAGCGAGCTTG-3'(SEQ ID NO.: 85, *FLP/TFC*)

and to substitute the ARS/CEN cassette from pZ₃ with these amplified products.

Another way is to substitute the 2μ-ori sequence from the plasmid p195 with the aforementioned PCR-products.

Advantageously, the vector comprises a selectable marker. The term selectable marker refers to a nucleic acid sequence whose expression confers a phenotype facilitating identification of cells containing the nucleic acid sequence. Selectable markers include those which confer resistance to toxic chemicals (= dominant marker, e.g. G418, hygromycin, formaldehyde, phleomycin or fluoroacetate like reviewed in Van den Berg, M. et al, 1997, Yeast 13, 551-9) or complement an auxotrophy (=auxotrophic marker, e.g. uracil, histidine, leucine, tryptophane). Auxotrophic selection markers can be used for naturally auxotrophic *Z. bailii* strains or strains that have been rendered auxotrophic by genetical manipulation, in particular by (partial) deletion or mutagenisation of an essential gene, e.g. *HIS3* (Branduardi, P., 2002, Yeast 19, 1165-70). As complementing marker sequence the homologous gene from *Z. bailii* or a heterologous gene might be employed. Auxotrophic markers are preferred since no component has to be added to the medium to keep the selective pressure during the cultivation.

The term “promoter” or “promoter region” refers to a DNA sequence, usually found upstream (5') to a coding sequence, that controls expression of the coding sequence by controlling production of messenger RNA (mRNA) by providing the recognition site for RNA polymerase and/or other factors necessary for start of transcription at the correct site. The promoter can be derived from any organism. Preferably the promoter is derived from a yeast, even more preferably from *Saccharomyces*, *Kluyveromyces* or *Zygosaccharomyces* and most preferably from *Z. rouxii* or *Z. bailii*. The promoter can be constitutive, inducible or repressible. Inducible promoters can be induced by the addition to the medium of an appropriate inducer molecule or by an appropriate change of the chemical or physical growth environment (such as the temperature or pH value), which will be determined by the identity of the promoter. Repressible promoters can be repressed by the addition to the medium of an appropriate repressor molecule or by an appropriate change of the chemical or physical growth environment (such as the temperature or pH value), which will be determined by the identity of the promoter. Constitutive promoters are preferred, as the use of an appropriate repressor or inducer molecule or an appropriate change of the chemical or physical growth environment is not required. Preferably the promoter is selected from the list of: triose-phosphate isomerase (TPI), glyceraldehyde phosphate dehydrogenase (GAPDH), alcohol dehydrogenase 1 (ADH1), phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAP), GAL1, GAL10, acid phosphatase (PHO5), cytochrome C-1 (CYC1), copper-binding metallothionein (CUP1) or a-factor mating pheromone precursor (Mfa1) promoter or the hybrid promoters GAL/CYC1, such as GAL1-10/CYC1, GAP/GAL, PGK/GAL, GAP/ADH2, GAP/PHO5 or CYC1/GRE either from *S. cerevisiae*, *Z. rouxii* or *Z. bailii*, but preferred from *Z. bailii*. Especially preferred promoters are the TPI promoters either from *S. cerevisiae* corresponding to SEQ ID No.: 78 or *Z. bailii* corresponding to SEQ ID No.: 79, but particularly preferred is the TPI promoter from *Z. bailii* (SEQ ID No.: 79). Further particularly preferred promoters are the GAPDH promoters from *Z. rouxii* (SEQ ID No.: 92) or *Z. bailii*.

Furthermore the vector comprises preferably a transcriptional terminator sequence following the coding sequence for the desired protein for efficient mRNA 3' end formation. Such a terminator sequence is preferably derived from a yeast, more preferably from *Saccharomyces* or *Zygosaccharomyces*, even more preferably from *S. cerevisiae* or *Z. bailii* and most preferably from *Z. bailii*. A preferred example for a terminator sequence comprises the following tripartite consensus

sequence: TAG..(T-rich)..TA(T)GT..(AT-rich)..TTT. Another preferred example comprises the sequence motif TTTTTATA.

Further the vector comprises a signalling sequence (=leader sequence; upon expression translated into signal peptide or leader peptide). Such sequences lead to the direction of expressed proteins from the cytosol into the culture medium. In other words signal sequences cause the secretion of the proteins and their accumulation in the medium. Signal sequences generally code for a continuous stretch of amino acids, typically 15 to 60 residues long (up to 150), which characteristically include one or more positively charged amino acid(s) followed by a stretch of about 5 to 10 hydrophobic amino acids, which may or may not be interrupted by non-hydrophobic residues. Preferably the signal peptide comprises 15-45 amino acids, even more preferably 15 to 30 amino acids. Even though their amino acid sequences can vary greatly, the signal peptides of all proteins having the same destination in one organism are functionally interchangeable: physical properties, such as hydrophobicity or the pattern of charged amino acids, often appear to be more important in the signal-recognition process than the exact amino acid sequence.

Preferably the DNA sequence coding for the signal peptide is selected from the list of: SEQ ID NO.: 1, SEQ ID NO.: 3, SEQ ID NO.: 5, SEQ ID NO.: 7, SEQ ID NO.: 9, SEQ ID NO.: 11, SEQ ID NO.: 13, SEQ ID NO.: 15, SEQ ID NO.: 17, SEQ ID NO.: 19, SEQ ID NO.: 21, SEQ ID NO.: 23, SEQ ID NO.: 25, SEQ ID NO.: 27, SEQ ID NO.: 29, SEQ ID NO.: 31, SEQ ID NO.: 33, SEQ ID NO.: 35, SEQ ID NO.: 37, SEQ ID NO.: 39, SEQ ID NO.: 41, SEQ ID NO.: 43, SEQ ID NO.: 45, SEQ ID NO.: 47, SEQ ID NO.: 49, SEQ ID NO.: 51, SEQ ID NO.: 53, SEQ ID NO.: 55, SEQ ID NO.: 57, SEQ ID NO.: 59, SEQ ID NO.: 61. Even more preferably the amino acid sequence of the signal peptide is selected from the list of: SEQ ID NO.: 2, SEQ ID NO.: 4, SEQ ID NO.: 6, SEQ ID NO.: 8, SEQ ID NO.: 10, SEQ ID NO.: 12, SEQ ID NO.: 14, SEQ ID NO.: 16, SEQ ID NO.: 18, SEQ ID NO.: 20, SEQ ID NO.: 22, SEQ ID NO.: 24, SEQ ID NO.: 26, SEQ ID NO.: 28, SEQ ID NO.: 30, SEQ ID NO.: 32, SEQ ID NO.: 34, SEQ ID NO.: 36, SEQ ID NO.: 38, SEQ ID NO.: 40, SEQ ID NO.: 42, SEQ ID NO.: 44, SEQ ID NO.: 46, SEQ ID NO.: 48, SEQ ID NO.: 50, SEQ ID NO.: 52, SEQ ID NO.: 54, SEQ ID NO.: 56, SEQ ID NO.: 58, SEQ ID NO.: 60, SEQ ID NO.: 62. Particularly preferred the DNA sequence coding for the signal peptide is selected from the list of SEQ ID NO.: 1, SEQ ID NO.: 3, SEQ ID NO.: 21 or SEQ ID NO.: 35 correspondingly the amino acid sequence of the signal peptide is preferably

selected from the list of SEQ ID NO.: 2, SEQ ID NO.: 4, SEQ ID NO.: 22 or SEQ ID NO.: 36.

The signal peptide is preferably removed from the finished protein. This can occur through activity of a specialised signal peptidase. The signal peptidase can be of homologous or heterologous origin. Therefore, the signal peptide comprises preferably a processing site or a cleavage site that allows for recognition by a specific endopeptidase.

In a preferred embodiment of the present invention the *Z. bailii* strain is transformed with a vector comprising the DNA sequence coding for the protein,

functionally linked to the signalling pre-sequence (16 aa) of the alpha-subunit of the K1 killer toxin of *K. lactis* (Stark M.J. et al., 1986, EMBO J. 5,1995-2002, SEQ ID NO.: 35 (DNA) and SEQ ID NO.: 36 (peptide)) and further functionally linked to the TPI promoter from *S. cerevisiae*. More preferably the vector is pZ₃kl (Figure 1b). Even more preferably the *Z. bailii* strain is transformed with a vector

comprising the DNA sequence coding for the protein, functionally linked to the signal sequence of the K1 killer toxin of *K. lactis* and further functionally linked to the GAPDH promoter from *Z. rouxii*. Even more preferably the *Z. bailii* strain is transformed with a vector comprising the DNA sequence coding for the protein, functionally linked to the signal sequence of the K1 killer toxin of *K. lactis* and further functionally linked to the TPI promoter from *Z. bailii*. Particularly preferred said vector is derived from pZ₃bT (Figure 4a).

In another preferred embodiment of the present invention the *Z. bailii* strain is transformed with a vector comprising the DNA sequence coding for the protein, functionally linked to the signal sequence of the pre-pro α-factor of *S. cerevisiae* and further functionally linked to the TPI promoter from *S. cerevisiae*. Preferably the vector is pZ₃ppα (Figure 1c). Even more preferably the *Z. bailii* strain is transformed with a vector comprising the DNA sequence coding for the protein, functionally linked to the signal sequence of the pre-pro α-factor of *S. cerevisiae* and further functionally linked to the GAPDH promoter from *Z. rouxii*. Even more

preferably the *Z. bailii* strain is transformed with a vector comprising the DNA sequence coding for the protein, functionally linked to the signal sequence of the pre-pro α-factor of *S. cerevisiae* and further functionally linked to the TPI promoter from *Z. bailii*. Particularly preferred said vector is derived from pZ₃bT (Figure 4a).

In yet another preferred embodiment of the present invention the *Z. bailii* strain is transformed with a vector comprising the DNA sequence coding for the protein,

functionally linked to the zygomycin killer toxin pre-sequence of *Z. bailii* (SEQ ID No.: 59) and further functionally linked to a promoter functional in *Z. bailii*. Preferably said promoter is the TPI promoter from *S. cerevisiae*. Even more preferably said promoter is the TPI promoter from *Z. bailii*. Most preferred is the 5 GAPDH promoter from *Z. rouxii*.

The DNA sequence coding for the protein can be derived from animal, bacterial, fungal, plant or viral sources, more preferably from metazoan, mammalian or fungal sources. The expressed protein might therefore be homologous or heterologous to *Z. bailii*.

10 Any yeast belonging to the species *Z. bailii* can be used for the production of proteins in the scope of the present invention. In a preferred embodiment of the invention the *Z. bailii* strain is transformed. "Transformation" refers to a process of introducing an exogenous nucleic acid sequence (of homologous and/or heterologous origin, recombinant or not) into a cell in which that exogenous 15 nucleic acid is incorporated into a chromosome or is capable of autonomous replication. A cell that has undergone transformation, or a descendant of such a cell, is "transformed" or "recombinant". If the exogenous nucleic acid comprises a coding region encoding a protein and the protein is produced in the transformed yeast such a transformed yeast is functionally transformed. Preferred methods to 20 transform *Z. bailii* are electroporation, as described in [WO 00/41477], or the chemical LiAc/PEG/ssDNA method as described by Agatep, R. et al., 1998, Technical Tips Online (<http://tto.trends.com>).

Preferably the *Z. bailii* strain that is being transformed is selected from the list of: ATCC 36947, ATCC 60483, ATCC 8766, FRR 1292, ISA 1307, NCYC 128, 25 NCYC 563, NCYC 1416, NCYC 1427, NCYC 1766, NRRL Y-2227, NRRL Y-2228, NRRL Y-7239, NRRL Y-7254, NRRL Y-7255, NRRL Y-7256, NRRL Y-7257, NRRL Y-7258, NRRL Y-7259, NRRL Y-7260, NRRL Y-7261, NRRL Y-27164; particularly preferred are ATCC 36947, ATCC 60483, ATCC 8766 and NCYC 1427.

30 (ATCC: American Type Culture Collection, Manassas VA, USA; FRR: FRR Culture Collection, North Ryde NSW, Australia; ISA: Culture Collection of the Instituto Superior de Agronomia, Lisbon; NCYC: National Collection of Yeast Cultures, Norwich, UK; NRRL: Agricultural Research Service Culture Collection, Peoria IL, USA).

35 Within the scope of the present invention the *Z. bailii* strain can be subjected to a selection process for improved secretion. Screening for and isolation of such a

"super-secreting" phenotype can occur before or after transformation of the respective *Z. bailii* strain.

In a preferred embodiment of the present invention the *Z. bailii* gene/s homologous to *GAS1* from *S. cerevisiae* are identified and disrupted. *GAS1* is one example for the few cases wherein the key molecules involved in the intriguingly complex secretory pathway have been identified. It was possible to influence the whole secretory mechanism modifying the *Gas1* expression level in *S. cerevisiae* (Vai, M., et al., 2000, Appl. Environ. Microbiol. 66, 5477-9) due to a resultant modification of the organisation of the cell wall structure, namely it was demonstrated that *gas1* mutants show a "super-secreting" phenotype (Popolo L., et al., 1997, J. Bacteriol. 180, 163-6; Ram A. F. J., et al., 1998, J. Bacteriol. 180, 1418-24).

In another preferred embodiment of the present invention the *Z. bailii* strain has undergone one or more mutagenisation/selection cycle(s) to obtain super secreting mutants, comprising chemical or physical mutagenesis. Preferably the mutagenisation is caused by orthovanadate. Orthovanadate is a molecule known to affect the glycosylation process and the cell wall construction in *S. cerevisiae* (Kanik-Ennulat, C. et al., 1990, Mol. Cell. Biol. 10, 898-909). Methods involving orthovanadate mutagenisation to obtain cells with changed cell wall construction/secretory properties that are useful in the scope of the present invention are disclosed in more detail for example for *S. cerevisiae* (Willsky, G.R., et al., 1985, J. Bacteriol. 164, 611-7) and *K. lactis* (Uccelletti, D., et al., 1999, Res. Microbiol. 150, 5-12; Uccelletti. D., et al., 2000, Yeast 16, 1161-71).

Culturing techniques and media suitable for yeast are well known in the art. Typically, but it is not limited to, culturing is performed by aqueous fermentation in an appropriate vessel. Examples for a typical vessel for yeast fermentation comprise a shake flask or a bioreactor.

The culture is typically performed at a temperature between 20°C and 40°C, preferably between 25°C and 35°C and even more preferred between 28°C and 32°C.

The medium in which the *Z. bailii* strain is cultured can be any medium known in the art to be suitable for this purpose. The medium might contain complex ingredients or might be chemically defined. Chemically defined media are preferred. The medium comprises any component required for the growth of the yeast. In particular the medium comprises a carbon source, such as fructose, glucose or other carbohydrates (such as sucrose, lactose, D-galactose, or

hydrolysates of vegetable matter, among others). Typically, the medium also comprises further a nitrogen source, either organic or inorganic, and optionally the medium may also comprise macro nutrients and/or micro nutrients such as amino acids; purines; pyrimidines; corn steep liquor; yeast extract; protein hydrolysates, 5 such as peptone; vitamins (water-soluble and/or water-insoluble), such as B complex vitamins; or inorganic salts such as chlorides, hydrochlorides, phosphates, or sulphates of Ca, Mg, Na, K, Fe, Ni, Co, Cu, Mn, Mo, or Zn, among others. Antifoam might be added, if necessary. Further components known to one of ordinary skill in the art to be useful in yeast culturing or fermentation can also 10 be included. The medium may or may be not buffered. A preferred medium comprises yeast extract, peptone and glucose (=YPD). A more preferred medium comprises yeast extract, peptone and fructose (=YPF). An even more preferred medium comprises glucose and Yeast Nitrogen Base (YNB, Difco Laboratories, Detroit, MI #919-15). Another even more preferred medium comprises fructose 15 and YNB.

Particularly preferred is a medium comprising high fructose corn syrup as carbon source (for example Isosweet® 100 42% High Fructose (80% solids) or Isosweet® 5500 55% Fructose from Tate & Lyle PLC or IsoClear® 42% High Fructose Corn Syrup or IsoClear® 55% High Fructose Corn Syrup from Cargill, Inc.). 20

The compositions of preferred media for batch/fed batch cultivation of *Z. bailii* according to the instant invention are as follows: the batch phase medium comprises 4% w/V Glucose, 0.5% w/V $(\text{NH}_4)_2\text{SO}_4$, 0.05% w/V MgSO_4 , 0.3% w/V KH_2PO_4 , vitamins according to Verduyn, C., et al., 1992, Yeast 8, 501-17, 25 wherein the final concentration of vitamins will be 3 times in respect to the indicated concentrations and trace elements according to Verduyn, C., et al., 1992, Yeast 8, 501-17, wherein the final concentration will also be 3 times in respect to the indicated concentrations. The pH control (value: pH 5) is performed by the addition of 2M KOH. The fed-batch medium comprises 50% w/V Glucose, 30 15.708 g/l KH_2PO_4 , 5 g/l KCl, 5.831 g/l MgSO_4 , 1,2 g/l CaCl_2 , 1 g/l Yeast Extract, 0.4447 g/l NaCl, 1 g/l Glutamate, 0,05 g/l ZnSO_4 , 0,04 g/l CuSO_4 , 0,05 g/l MnCl_2 , 0,001 g/l CoCl_2 , 0.5 g/l myo-inositol, 0.1 g/l thiamine hydrochloride, 0.02 g/l pyridoxol hydrochloride, 0.04 g/l Ca-D(+)panthotenate, 0.004 g/l d-biotin, 0.09 g/l nicotinic acid. The pH control (value: pH 5) is performed by the addition 35 of 2M NH_4OH .

In case of selection for the dominant G418 marker 200mg/l G418 is added to the respective medium.

The use of a defined medium, of which the components are adjusted to the needs of the organism is preferred. The purification of the protein is thereby significantly simplified.

Preferably, the pH of the culture medium ranges between 2 and 9, more preferably between 3 and 8 and even more preferably between 4 and 7. The pH can be regulated or partially regulated or not be regulated during the course of fermentation; accordingly the pH can be kept constant at a preferred value or can change during fermentation. A significant advantage of *Z. bailii* is its surprising capacity to grow as well as express and secrete proteins at low pH. Therefore, the demand of this organisms for a strictly controlled pH is not very pronounced.

The cultivation can take place in batch, fed-batch or continuous mode as is known to the ordinary skilled artisan.

During the course of the fermentation, the desired protein is expressed, properly processed (i.e. folded, modified, cut, etc.) and secreted (=accumulated in the medium). While the protein produced may be partially retained within the yeast cells it is preferred that a substantial amount of the protein is secreted. Even more preferred is that the protein is entirely secreted.

After culturing has progressed for a sufficient length of time to produce a desired concentration of the protein in the yeast and/or the culture medium, the protein is isolated. "Isolated," as used herein to refer to the protein, means being brought to a state of greater purity by separation of the protein from at least one other component of the yeast or the medium. Preferably, the isolated protein is at least about 80% pure as based on the weight, more preferably at least about 90% pure as based on the weight and even more preferably at least about 95% pure as based on the weight. Evidence of purity can be obtained by SDS-PAGE, 2D electrophoresis, IF, HPLC, mass spectrometry, capillary electrophoresis or other methods well known in the art.

"Purity" refers to the absence of contaminants in the final purified protein. Typical contaminants to be separated from the desired product are proteins, pyrogens, nucleic acids and more.

The protein is isolated from the culture medium, preferably without lysing of the cells. Such an isolation comprises purifying the protein from the medium.

Purification can be achieved by techniques well-known in the art, such as filtration

(e.g. microfiltration, ultrafiltration, nanofiltration), crystallisation or precipitation, centrifugation, extraction, chromatography (e.g. ion exchange, affinity, hydrophobic exchange), among others.

Upon removal of the cells, the culture broth might also directly serve as the product (e.g. enzyme solution), without further purification. The medium components can be adjusted appropriately prior to the cultivation.

If the protein is not completely secreted, the protein can also be isolated from both the yeast cells and the medium. Methods for lysing of the yeast cells are known in the art and comprise chemical or enzymatic treatment, treatment with glass beads, sonication, freeze/thaw cycling, or other known techniques. The protein can be purified from the various fractions of the yeast lysate by appropriate techniques, such as filtration (e.g. microfiltration, ultrafiltration, nanofiltration), crystallisation or precipitation, centrifugation, extraction, chromatography (e.g. ion exchange, affinity, hydrophobic exchange), among others.

Another embodiment of the present invention relates to a *Z. bailii* strain, expressing and secreting a heterologous protein.

The *Z. bailii* strain might be transformed with a vector comprising a DNA sequence coding for the heterologous protein, functionally linked to a signal sequence leading to the secretion of the protein and further functionally linked to a promoter.

Description of the Figures:

Figure 1: Expression and Secretion Vectors

Schematic maps of the plasmids constructed for expression of proteins in *Z. bailii*:

a : pZ₃, (intracellular expression), **b** : pZ₃kl (expression and secretion) and **c** : pZ₃ppα (expression and secretion).

a) pZ₃ : the backbone of the plasmid is the pYX022 *S. cerevisiae* expression plasmid (R&D Systems, Inc., Wiesbaden, D; the expression cassette is based on the constitutive *S. cerevisiae* TPI promoter and the corresponding polyA signal, as indicated in the Figure). The ARS/CEN fragment, from Ycplac33 (Gietz, R. D., et al., 1988, Gene 74, 527-34) ensures replication and stability of the plasmid, while

the Kan^R cassette, derived from pFA6-KanMX4 (Wach, et al., 1994, Yeast 10, 1793-808) allows a G418-based selection of the transformants.

b) pZ₃kl: a pZ₃ expression vector comprising the signal sequence of the *K. lactis* K1 killer toxin (kl) for leading the secretion of the protein of interest.

5 c) pZ₃ppα: a pZ₃ expression vector comprising the pre-pro leader sequence of the *S. cerevisiae* pheromone α-factor (pre-pro-αF) for leading the secretion of the protein of interest.

(Amp= ampicillin resistance cassette; MCS= multi cloning site; colE1 ori; *E. coli* replication origin)

10

Figure 2: Expression and Secretion Vectors

Schematic maps of the plasmids constructed for expression and secretion of the human IL-1β (Auron, E., et al., 1984, PNAS 81, 7907-11) and the GFP (Heim, R. et al., 1996, Curr. Biol. 6, 178-82) in *Z. bailii*.

15 a) pZ₃klIL-1β: a pZ₃kl vector where the sequence encoding for the human IL-1β was sub-cloned into the MCS.

b) pZ₃ppαIL-1β: a pZ₃ppα vector where the sequence encoding for the human IL-1β was sub-cloned into the MCS.

20 c) pZ₃ ppαGFP: a pZ₃ppα vector where the sequence encoding for the GFP was sub-cloned into the MCS.

Figure 3: Expression and Secretion Vectors

Schematic maps of the plasmids constructed for the expression of the *Arxula adeninivorans* glucoamylase (GAA, Genebank accession no: Z46901, Bui Minh, D., et al., 1996, Appl. Microbiol. Biotechnol. 44, 610-9) and of the bacterial β-galactosidase (from the plasmid pSV-β-galactosidase of Promega, Inc.; Genebank accession no.: X65335) in *Z. bailii*.

a) pZ₃GAA: a pZ₃ vector where the sequence encoding for the glucoamylase (GAA) was sub-cloned into the MCS.

b) pZ₃LacZ: a pZ₃ vector where the sequence encoding for the β-galactosidase was sub-cloned into the MCS.

5

Figure 4: Expression Vectors

Schematic maps of the plasmids constructed for the expression of proteins in *Z. bailii* based on the *Z. bailii TPI* promoter.

a) pZ₃bT: a pZ₃ vector where the *S. cerevisiae TPI* promoter was substituted by

10 the *Z. bailii TPI* promoter.

b) pZ₃bTLacZ: a pZ₃bT expression vector where the sequence encoding for the β-galactosidase was sub-cloned into the MCS.

Figure 5: IL-1β secretion

15 a) Growth kinetics in minimal (YNB) and rich (YPD) medium, with glucose 5% (w/V) as a carbon source: the cellular growth was measured as optical density (OD 660nm, circles) and the residual glucose (g/l, squares) was evaluated. Comparison between *S. cerevisiae* (open symbols) and *Z. bailii* (full symbols).

b) Western Blot analyses performed on cellular extracts of *S. cerevisiae* and *Z. bailii* cells transformed with the plasmid pZ₃k1IL-1β (expressing IL-1β preceded by the leader sequence from the *K. lactis* killer toxin) and with the corresponding empty plasmid (pZ₃), as a negative control. In the first lane a positive control (IL-1β, human recombinant (*E. coli*), Roche cat n° 1 457 756) was loaded. Samples were collected at the indicated times and from the indicated media, corresponding to the kinetics showed in (a). The loaded volumes were rectified for a corresponding OD value of 0.08. The blotted membranes were probed with an α-IL-1β polyclonal antibody.

c) as above, were the loaded samples represent the corresponding supernatant.

d) as above, were the samples were loaded with an equal volume of medium (30µl).

Figure 6: Leading of the pre-pro- α -factor signal sequence to the secretion of IL-

5 1 β and of GFP in *Z. bailii*

a) Western Blot analyses performed on cellular extracts (i) and on supernatants (ii) of *Z. bailii* and *S. cerevisiae* cells transformed with the plasmid pZ₃ppαIL-1 β (and with the corresponding empty plasmid pZ₃) and growing on YPD medium (glucose 2% w/V). Samples were taken at the indicated times. First lane: positive 10 control (IL-1 β , human recombinant (*E. coli*), Roche cat n° 1 457 756). The blotted membranes were probed with an α -IL-1 β polyclonal antibody.

Western Blot analyses performed on cellular extracts (iii) and on supernatants (iv) of *Z. bailii* and *S. cerevisiae* cells transformed with the plasmid pZ₃ppαIL-1 β (and with the corresponding empty plasmid pZ₃) and growing on YNB medium (glucose 5% w/V). Samples were taken at indicated times. First lane: positive 15 control (IL-1 β human recombinant (*E. coli*) Roche cat n° 1 457 756). The blotted membranes were probed with an α -IL-1 β polyclonal antibody.

b) Western Blot analyses performed on cellular extracts (cells) and on supernatants (sup) of *Z. bailii* cells growing on YNB medium (glucose 2% w/V) 20 transformed with the control plasmid pZ₃ (1st and 2nd lanes) and with the plasmid pZ₃ppαGFP (3rd and 4th lanes). The blotted membrane was probed with an α -GFP polyclonal antibody. An arrow indicates the expected positive signal.

Figure 7: Batch cultivations of *Z. bailii* cells comprising the pZ₃klIL-1 β

25 expression plasmid on chemically defined medium in high sugar concentration

a) Culture OD (full circles), dry weight (open circles), glucose consumption (full squares) and ethanol production (open triangle).

b) Western Blot analyses performed on the growth medium (lane 2 to 5) and on the cell extracts (lanes 6 to 9) of *Z. bailii* cells. Samples were collected at the 30 indicated times of the kinetics, and an equal volume (30µl for the supernatants and

15 μ l for the cell extracts, respectively) was loaded. The blotted membranes were probed with an α -IL-1 β polyclonal antibody.

First lane: positive control (IL-1 β human recombinant (*E. coli*) Roche cat n° 1 457 756).

5

Figure 8: Enzymatic activity of heterologous enzymes expressed in *Z. bailii* cells

a) Determination of the *A. adeninivorans* glucoamylase activity (mU/OD) present in the growth medium (YNB, glucose 2% w/V) of *Z. bailii* cells transformed with the plasmid pZ₃GAA (and the respective empty plasmid pZ₃, as a control). Three independent clones were analysed (Cl. 1, Cl. 3 and Cl. 5).

b) Determination of the β -galactosidase activity (Miller U/OD) in cell extracts of *Z. bailii* cells transformed with the plasmid pZ₃LacZ (two independent clones) and with the plasmid pZ₃bTLacZ (three independent clones), and the respective empty plasmid pZ₃ as a control. Cells were grown in YPD medium (glucose 2% w/V), and samples were collected at indicated times.

On the left panel the *Z. bailii* strain ATCC 36947, on the right panel the strain *Z. bailii* ATCC 60483 were tested, respectively.

Figure 9: Construction of a *Z. bailii* multicopy plasmid

20 Schematic maps of the endogenous plasmids isolated from *Z. bailii* ATCC 36947, named pZB₁ (a) and from *Z. bailii* NCYC 1427, named pZB₅ (b).

c): *Z. bailii* multicopy expression vector comprising the genes and the sequences necessary and sufficient for a stable and autonomous high copy number replication. The expression cassette is based on the *Z. bailii* constitutive *TPI* promoter and the polyA, as indicated in the Figure. The marker for selection is the Kan^R cassette.

d) *Z. bailii* multicopy expression vector. The expression cassette is based on the *Z. bailii* constitutive *TPI* promoter and the polyA, as indicated in the Figure. Furthermore, the vector comprises the IR/ARS region and the TFC/FLP genes including their homologous promoters as indicated.

30

Figure 10: Influence of the promoter or the plasmid constituents, respectively, on β-galactosidase activity.

Shown is the relative β-galactosidase activity in cell extracts of *Z. bailii* ATCC 36947 cells transformed with the indicated plasmids. The β-galactosidase activity of cells transformed with pZ₃LacZ was set to 1 and the other activities were related to that value. Cells were grown in YPD medium (glucose 2% w/V), and samples were collected as the cultures reached an OD⁶⁶⁰ value between 1 and 2.

a) Different promoters in the same plasmid. pZ₃: *ScTPI*, pZ₃bT: *ZbTPI*, pZ₃rG: *ZrGAPDH*.

b) Different plasmid constituents. pZ₃: *Sc ARS/CEN*, p195: *Sc 2μm ori sequence*, pEZ-IA: *Zb 2μm ori sequence (IR-A)*, pEZ-IAF: *Zb 2μm ori sequence (IR-A) + FLP*, pEZ₂: *Zb 2μm ori sequence (IR-A) + FLP + TFC*, pEZ₂-IB: *Zb 2μm ori sequence (IR-A) + FLP + TFC + IR-B*. The table indicates the determined plasmid stability of the respective constructs.

15

Figure 11: Leading of the zygocin pre-sequence to the secretion of IL-1β and comparison of different leader sequences

a) Western Blot analyses performed on cellular extracts (*i*) and on supernatants (*ii*) of *Z. bailii* and *S. cerevisiae* cells transformed with the plasmid pZ₃kbIL-1β (and with the corresponding empty plasmid pZ₃) and growing on YPD medium (glucose 2% w/V). Samples were taken at the indicated times. First lane: positive control (IL-1β, human recombinant (*E. coli*), Roche cat n° 1 457 756). The blotted membranes were probed with an α-IL-1β polyclonal antibody.

Western Blot analyses performed on cellular extracts (*iii*) and on supernatants (*iv*) of *Z. bailii* and *S. cerevisiae* cells transformed with the plasmid pZ₃kbIL-1β (and with the corresponding empty plasmid pZ₃) and growing on YNB medium (glucose 5% w/V). Samples were taken at the indicated times. The blotted membranes were probed with an α-IL-1β polyclonal antibody.

b) Western Blot analyses performed on supernatants of *Z. bailii* cells growing on YNB medium (glucose 2% w/V) transformed with the indicated plasmids. The blotted membranes were probed with an α-IL-1β polyclonal antibody.

Figure 12: Glucoamylase Sta2 activity in transformed *Z. bailii* or *S. cerevisiae* cells, respectively

Determination of the *S. cerevisiae* var. *diastaticus* glucoamylase Sta2 activity
5 (U/OD) in the growth medium (YNB, fructose 2% w/V) of *Z. bailii* and *S.*
cerevisiae cells transformed with the plasmids pZ₃STA2 and pZ₃klSTA2 and the
respective empty plasmid pZ₃, as a control (as indicated). In the first plasmid the
protein is lead to secretion from its own leader sequence, in the second from the
10 *K. lactis* killer toxin pre-leader sequence. Measurements were repeated more times
and on independent clones, and variation levels are indicated with error bars.

Examples:

The following examples are included to demonstrate preferred embodiments of
15 the invention. It should be appreciated by those of skill in the art that the
techniques disclosed in the examples which follow represent techniques
discovered by the inventors to function well in the practice of the instant
invention, and thus can be considered to constitute preferred modes for its
20 practice. However, those of skill in the art should, in light of the present
disclosure, appreciate that many changes can be made in the specific embodiments
which are disclosed and still obtain a like or similar result without departing from
the spirit and scope of the invention.

Example 1: construction of *Z. bailii* expression plasmids

25 The Backbone of the new vector pZ₃ (Fig. 1a) is the basic *S. cerevisiae* expression
plasmid YX022 (R&D Systems, Inc., Wiesbaden, D).
The ARS1-CEN4 fragment was taken from Ycplac33 (ATCC 87623, Genbank
accession no.: X75456 L26352,). It was cutted ClaI-blunt/SpeI and cloned into
pYX022 opened DraIII-blunt/SpeI (in this way the plasmid lost completely the
30 *HIS* gene).

The plasmid obtained was opened KpnI-blunt, and here the Kan cassette, derived from pFA6-KanMX4 (Wach et al., 1994 *Yeast* 10, 1793-1808) was inserted. The respective fragment was taken out cutting with SphI/SacI-blunt. This kanMX module contains the known kan^r open reading-frame of the *E. coli* transposon

5 Tn903 fused to transcriptional and translational control sequences of the *TEF* gene of the filamentous fungus *Ashbya gossypii* (e.g. NRRL Y-1056). The described hybrid module permits efficient selection of transformants resistant against geneticin (G418).

10 The expression cassette based on the constitutive *S. cerevisiae* TPI promoter and the respective polyA, interspaced by the multi cloning site (MCS), as indicated in the Figure derives from the original pYX022 plasmid (see supplier's information).

All the other plasmids indicated in the Figures 1 to 4 derive from pZ₃.

15 For the construction of the plasmid pZ₃kl (Fig. 1b), the signalling pre-sequence (16 aa) of the alpha-subunit of the K1 killer toxin of *K. lactis* (Stark M.J. et al., 1986, EMBO J. 5, 1995-2002) was functionally linked to the TPI promoter of the pZ₃ plasmid, in order to lead the secretion of the protein of interest.

For the construction of the plasmid pZ₃ppα (Fig. 1c), the pre-pro-α-factor signal sequence was similarly utilised and functionally inserted. The sequence was taken from the plasmid pPICZαA (Invitrogen BV, The Netherlands)

20 For the construction of the plasmid pZ₃klIL-1β (Fig. 2a), the coding sequence for the protein already fused with the killer toxin *K. lactis* signal sequence was taken cutting XbaI/EcoRI-bluntended from the plasmid pCXJ-kan1 (Fleer R, et al., 1991, Gene 107, 285-95) and sub-cloned into the plasmid pZ₃ EcoRI bluntended and de-phosphorylated.

25 For the construction of the plasmid pZ₃ppαGFP (Fig. 2c), the fragment containing the α-factor pre-pro leader sequence in frame with the GFP coding sequence was cutted HindIII bluntended/BamHI from the plasmid pPICAGFP1 and sub-cloned in the plasmid pZ₃ opened EcoRI bluntended/BamHI and de-phosphorylated. The plasmid pPICAGFP1 was constructed according to Passolunghi, S., et al. by introduction of a PCR amplified GFP sequence in frame into the plasmid pPICZαA (Invitrogen BV, The Netherlands). The PCR technique is known in the art. Exemplary reference is made to Gelfand, D. H., et al., PCR Protocols: A

Guide to Methods and Applications, 1990, Academic Press and Dieffenbach, C. W. et al., PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1995.

For the construction of the plasmid pZ₃ppαIL-1β (Fig. 2b), the IL-1β was PCR
5 amplified from the plasmid pZ₃klIL-1β.

The oligos for the amplification are the following:

Primer: DrdI-IL (SEQ ID NO.: 80)

5' AAGAGACTCCAACGTCGCGCACCTGTA 3' Tm: 63°C

Primer: IL C-term (SEQ ID NO.: 81)

10 5' AGAGGATTAGGAAGACACAAATTGCATGGTGA 3' Tm: 61°C

The following program was used for the amplification:

94°C	5min	
94°C	45s	
27°C	45s	{ 10 cycles
72°C	2min	
94°C	45s	
50°C	45s	{ 20 cycles
72°C	2min	
72°C	7min	
4°C	∞	

In this way a DrdI cutting site for sub-cloning the coding sequence of the IL-1β
15 protein in frame with the α-factor pre-pro leader sequence was introduced. The
plasmid pZ₃ppαGFP was opened EcoRI blunted/BamHI. The PCR fragment
was cutted DrdI blunted/BamHI. Combination resulted in the plasmid
pZ₃ppαIL-1β.

In the plasmid pZ₃kbIL-1β, the coding sequence of the interleukin was
20 functionally linked to the deduced pre-leader sequence of the *Z. bailii* killer toxin
zygocin (Genebank accession no.: AF515592; Weiler F. et al., 2002, Mol
Microbiol. 46, 1095-105.). Essentially oligonucleotides were synthesized
corresponding to the deduced pre-leader sequence of the *Z. bailii* killer toxin
zygocin (SEQ ID No.: 59) and cloned into the plasmid pZ₃. Subsequently, the IL-

1 β was PCR amplified as explicated before and cloned in-frame to the zygocin pre-sequence.

For the construction of the plasmid pZ₃GAA (Fig. 3a), the coding sequence of the *A. adeninivorans* α -glucoamylase was cut BamHI blunted from the plasmid 5 pTS32x-GAA (Bui D. M., et al., 1996, Appl. Microbiol. Biotechnol. 45, 102-6) and inserted in the plasmid pZ₃ opened EcoRI blunted and de-phosphorylated.

For the construction of the plasmid pZ₃STA2, the coding sequence of the *S. cerevisiae* var. *diastaticus* amylase (comprising its own leader sequence) was cut XbaI/AseI-blunt from the plasmid pMV35 (Vanoni M. et al., 1989, Biochim 10 Biophys Acta. 1008, 168-76) and inserted in the plasmid pZ₃ opened EcoRI-blunt.

For the construction of the plasmid pZ₃klSTA2, the coding sequence of the same amylase but functionally linked to the *K. lactis* killer toxin leader sequence was cut XhoI/AseI-blunt from the plasmid pMV57 (Venturini M. et al., 1997, Mol 15 Microbiol. 23, 997-1007) and inserted in the plasmid pZ₃ opened EcoRI-blunt.

15

For the construction of the plasmid pZ₃LacZ (Fig. 3b), the coding sequence of the bacterial β -galactosidase was cutted HindIII blunted/BamHI from the plasmid pSV- β -galactosidase (Promega, Inc.) and inserted into the plasmid pZ₃ opened EcoRI blunted/BamHI and dephosphorylated.

20

In the plasmid pZ₃bT (Fig. 4a), the *TPI* promoter of *S. cerevisiae* was substituted with the endogenous *TPI* promoter from *Z. bailii*. The sequence was PCR amplified from the genomic DNA of the *Z. bailii* strain ISA 1307, and the primers were designed according to the literature (Merico A., et al., 2001, Yeast 18, 775-80). Extraction of genomic DNA was performed according to the protocol 25 published by Hoffman, C. S., et al., 1987, Gene 57, 267-72).

The oligos for the amplification are the following:

TPIprob5 (SEQ ID NO.: 82)

5' ATCGTATTGCTTCCATTCTTCTTTGTTA 3' Tm: 59.6°C

TPIprob3 (SEQ ID NO.: 83)

30

5' TTTGTTATTGTTATACCGATGTAGTCTC 3' Tm: 59.6°C

The following program was used for the amplification:

94°C	5min	
94°C	45s	
57°C	45s	
72°C	1min 30s	
72°C	7min	
4°C	∞	

The PCR fragment was sub-cloned into the vector pST-Blue1 (Novagen, Perfect Blunt cloning Kit cat. no. 70191-4), according to the included protocol.

- 5 Therefrom, the promoter was cut SnaBI/SacI and sub-cloned into the pZ₃ opened AatII blunted/SacI (so to remove the *S. cerevisiae* TPI promoter), obtaining the desired plasmid.

For the construction of the plasmid pZ₃bTLacZ (Fig. 4b), the coding sequence of the bacterial β-galactosidase was cutted HindIII/BamHI blunted from the plasmid pSV-β-galactosidase (Promega, Inc.; Genebank accession no.: X65335) and inserted into the plasmid pZ₃bT opened NheI blunted and dephosphorylated.

In the plasmid pZ₃rG, the TPI promoter of *S. cerevisiae* was substituted with the GAPDH promoter from *Z. rouxii*. The sequence was PCR amplified from genomic DNA of the *Z. rouxii* strain LST11, and the primers were designed according to the literature (Ogawa Y. et al., 1990, Agric Biol Chem. 54, 2521-9). Extraction of genomic DNA was performed according to the protocol previously mentioned. (Another possible strain is *Z. rouxii* NRRL Y-229.)

The oligos for the amplification are the following:

- 20 pZrGAPDH_fwd (SEQ ID NO.: 93)
 5' TGCAGAAAGCCCTAACAGATGCT 3' Tm: 60.3°C
 pZrGAPDH_rev (SEQ ID NO.: 94)
 5' TGTCTGTGATGTACTTTTATTGATATG 3' Tm: 59.2°C

The following program was used for the amplification:

94°C	5min	
94°C	15s	}
57°C	30s	} 25 cycles
72°C	45s	J
72°C	7min	
4°C	∞	

The obtained PCR fragment (708 bp) was sub-cloned into the vector pST-Blue1 (Novagen, Perfect Blunt cloning Kit cat. no. 70191-4), according to the included

5 protocol. Therefrom, the promoter was cut SnaBI/SacI and sub-cloned into the pZ₃ opened AatII blunted/SacI (so to remove the *S. cerevisiae* TPI promoter), obtaining the desired plasmid.

For the construction of the plasmid pZ₃rGLacZ (Fig. 4b), the coding sequence of 10 the bacterial β-galactosidase was cut HindIII/BamHI blunted from the plasmid pSV-β-galactosidase (Promega, Inc.; Genebank accession no.: X65335) and inserted into the plasmid pZ₃rG opened XhoI blunted and de-phosphorylated.

DNA manipulation, transformation and cultivation of *E. coli* (DH5α), were performed following standard protocols (Sambrook J., et al., Molecular Cloning: 15 A Laboratory Manual, 2nd edn., Cold Spring Harbor Laboratory, New York, 1989). Also other basic molecular biology protocols were performed following this manual if not otherwise stated. All the restriction and modification enzymes utilised are from NEB (New England Biolabs, UK) or from Roche Diagnostics.

20 **Example 2:** Transformation of *Z. bailii*

Transformations of all the *Z. bailii* and the *S. cerevisiae* (NRRL Y-30320) strains were performed basically according to the LiAc/PEG/ss-DNA protocol (Agatep, R., et al., 1998, Transformation of *Saccharomyces cerevisiae* by the lithium acetate/single-stranded carrier DNA/polyethylene glycol (LiAc/ss-DNA/PEG) 25 protocol. Technical Tips Online (<http://tto.trends.com>)). After the transformation,

Z. bailii cells were recovered with an incubation of 16 hours in YP medium, comprising 2% w/V of fructose as carbon source (YPF), and 1 M sorbitol, at 30°C. The cell suspension was then plated on selective YPF plates with 200 mg/l G418 (Gibco BRL, cat. 11811-031). Single clones appeared after 2-3 days at 5 30°C. From then on the transformants were grown either in rich or in minimal medium having glucose as carbon source and 200 mg/l G418 for maintenance of the selection. For *S. cerevisiae* cells, the procedure was the same, except for the carbon source, that remained glucose in all the steps, and for the G418 concentration, optimised for our strain to 500 mg/l.

10

Example 3: Expression and secretion of Interleukin 1- β in *Z. bailii*

In order to check the secretory capability of the yeast *Z. bailii* and to compare it with the well known host *S. cerevisiae*, both yeasts were transformed (according to Example 2) with the plasmid pZ₃klIL-1 β (Fig. 2a). Independent transformants 15 were shake flask cultured in minimal medium (YNB, 1.34% w/V YNB from Difco Laboratories, Detroit, MI #919-15, 5% w/V Glucose, complemented with Histidine, Uracil and Leucine, Fig. 5a, left panel) or in rich medium (YPD, 5% w/V Glucose, 2% w/V Peptone, 1% w/V Yeast extract, Fig. 5a, right panel). Fig. 20 5a shows the cell density (OD 660nm) and the glucose consumption during the kinetics of growth. The glucose consumption was determined using a commercially available enzymatic kit from Boehringer Mannheim GmbH, Germany (Cat # 716251), according to the manufacturer's instructions. During the kinetics, samples were collected at the indicated times (see "hours" of Fig. 5b, c, d). Cells were harvested (a culture volume corresponding to 10⁸ cells) by 25 centrifugation (10 min 10.000 rpm). 1 volume 2X Laemmli Buffer (Laemmli, U.K., 1970, Nature 227, 680-5) was added to the supernatants of said samples, they were boiled 3-5 minutes and stored at -20°C until loading or loaded directly 30 on a polyacrylamide gel.

The cell pellets of said samples were resuspended in 5ml 20% TCA, centrifuged (10 min at 3000 rpm) and the resulting pellets were resuspended in 150 μ l 5% TCA. Samples were subsequently centrifuged for 10 min at 3000 rpm, and the

pellet was resuspended in Laemmli Buffer (100µl). In order to neutralise the samples, 1 M Tris base was added (50µl). After 3-5 min at 99°C the samples are ready to be loaded on a polyacrylamide gel (alternatively, they can be stored at -20°C).

- 5 Samples were loaded on standard polyacrylamide gels (SDS-PAGE, final concentration of the separating gel: 15%); after protein separation, gels were blotted (1 h, 250 mA) to nitrocellulose membranes (protran BA 85, Schleicher & Schuell). Immunodecoration: after 1h (RT) of saturation in TBS 1X (1.2 g/l Tris base; 9 g/l NaCl) + 5% NFM (non fat milk), 0.2% Tween-20, the membranes were
10 incubated overnight at 4°C with the primary antibody against interleukin (rabbit polyclonal antibody IL-1 β (H-153) from Santa Cruz Biotechnology, Inc. cat. n° sc-7884) diluted 1:200 in TBS 1X (1.2 g/l Tris base; 9 g/l NaCl) + 5% NFM. After intensive and repeated washes in TBS + 0.2% Tween-20, the secondary antibody (antirabbit IgG horseradish peroxidase-conjugated, Amersham Biosciences, UK cat
15 n° NA934) was added (1:10.000 in TBS 1X + 5% NFM) and left in incubation for 1h (RT). The proteins were visualised using ECL Western Blotting System (Amersham Biosciences, UK) according to the manufacturer's instructions.

The data obtained by Western Blot performed on the supernatant highlight the surprisingly good secretory capability of *Z. bailii* cells (see Fig. 5c), both in
20 minimal and in rich medium. Remarkably, the signal corresponding to the secreted protein is significantly more intense compared to the signal obtained from *S. cerevisiae* cells, in agreement with the lower signal revealed in *Z. bailii* crude cell extracts (Fig. 5b). Moreover, the difference in the secreted levels of proteins is even more pronounced in minimal medium respect than in rich medium (for a
25 comparison: Fig. 5c, left and right panel). These conclusions can be done either considering samples loaded rectifying the OD (Fig. 5c) or either considering equal volumes of loaded samples (Fig. 5d).

Similarly, *Z. bailii* and *S. cerevisiae* cells were transformed with the plasmid pZ₃ppαIL-1 β . In this case the same protein (interleukin) is functionally fused with
30 the leader sequence of the *S. cerevisiae* α-factor pheromone. As previously described, cells were shake flask cultured in rich YPD or in minimal YNB medium, samples were collected and prepared for protein SDS-PAGE separation.

The Western Blot (Fig. 6a) once more revealed the surprisingly better secretion occurring in *Z. bailii* if compared to *S. cerevisiae*: the signals obtained from the crude extracts (*i* for YPD, *iii* for YNB medium) are more intense in the latter strain, suggesting that the product is shorter retained and therefore more efficiently secreted from *Z. bailii* cells. This observation is consistent with the fact that the signals corresponding to the product secreted into the medium are more intense in *Z. bailii* samples than in *S. cerevisiae* ones (*ii* for YPD, *iv* for YNB medium; in this case a positive signal is present only in *Z. bailii* samples).

Importantly, the process of expression, secretion and accumulation of heterologous proteins in the culture medium can be obtained not only by changing the leader sequence, but also by utilising the same leader sequence but changing the heterologous protein expressed. *Z. bailii* cells were transformed with the plasmid pZ₃ppαGFP, shake flask cultured in minimal YNB medium, samples were collected and prepared for protein SDS-PAGE separation. The Western Blot analyses performed as previously described, except for the primary antibody utilised (anti-GFP, Clontech, Inc.) and its concentration (1:500), show a band of the expected dimension that is present only in the supernatant of the *Z. bailii* cells expressing the GFP heterologous protein (Fig. 6b) and not in the control strain, transformed with the empty plasmid.

The data obtained underline the possibility to utilise *Z. bailii* as a host for the process to express different heterologous proteins and to secrete them, leading the secretion with heterologous leader sequences. Remarkably, the level of secreted proteins are higher compared with the levels obtained in *S. cerevisiae*, and the difference is even more pronounced, in chemically defined culture medium.

25

Example 4: Expression and secretion of Interleukin 1-β in a *Z. bailii* bioreactor batch cultivation with high sugar concentration.

Z. bailii cells transformed (according to Example 2) with the plasmid pZ₃klIL-1β (Fig. 2a) and previously analysed for interleukin 1-β production in shake flask culture (see Example 3), were batch cultivated in a 2 l laboratory bioreactor (fermentor, Biolafitte & Moritz, Mod. Prelude - France) in a chemically defined

medium with high glucose content (27% w/V Glucose, 4% w/V $(\text{NH}_4)_2\text{SO}_4$, 0.4% w/V MgSO_4 , 2.4% w/V KH_2PO_4 , vitamins according to Verduyn, C., et al., 1992, Yeast 8, 501-17, wherein the final concentration of vitamins was set to be 24 times in respect to the indicated concentrations and trace elements according to
5 Verduyn, C., et al., 1992, Yeast 8, 501-17, wherein the final concentration of trace elements was also set to be 24 times in respect to the indicated concentrations. (Depending on the salt tolerance of the production strain it might be useful in this context to add only a partial quantity of the salts with the glucose to the initial medium and to add the rest of the salts after the bioreaction (fermentation) has
10 proceeded a sufficient amount of time.) The pH control (value: pH 5) is performed by the addition of 2M KOH. G418 was added to a concentration of 200mg/l G418, antifoam was added as necessary). The inoculum was prepared by pre-growing the yeast in shake flask (with a headspace-to-culture volume ratio of 4) in YPD rich medium (see above), with the addition of 200mg/l G418. Cells were harvested,
15 washed with deionised water and inoculated in the final medium at OD 1.68 in the bioreactor. Cell culture was flushed with 90 l/h of air and the dissolved oxygen concentration was maintained at 40% of air saturation, varying the stirrer speed. Fig. 7a shows the growth kinetics (cell density, OD 660nm), together with the glucose consumption, the ethanol production and the biomass produced (dry weight g/l). The glucose consumption and the ethanol production were determined
20 by using commercial enzymatic kits (Boehringer Mannheim GmbH, Germany Kits Cat # 716251 and 0176290, respectively), according to the manufacturer's instructions. The determination of the cellular dry weight (biomass) was performed as described before (Rodrigues, F. et al, 2001, Appl. Environ.
25 Microbiol. 67, 2123-8). Samples were collected at the indicated times and prepared for protein SDS-PAGE separation. The Western Blot analysis (performed as described in Example 3) shows a very strong and clean signal accumulating during time corresponding to the secreted product (lanes 2 to 5), and confirms the minimal retention of heterologous protein produced within the cells
30 (lanes 6 to 9, Fig. 7b). This example shows the surprising and advantageous characteristic of *Z. bailii* cells to be able to grow as well as express and secrete a heterologous protein even at very high sugar concentrations. Reportedly *S.*

cerevisiae does not grow any more or can grow only very poorly at such high sugar concentrations (see for example Porro, D., et al., 1991, Res. Microbiol. 142, 535-9).

5 **Example 5:** Expression and secretion of Glucoamylase in *Z. bailii*.

Z. bailii cells were transformed (according to Example 2) with the plasmid pZ₃GAA (Fig. 3), and with the empty plasmid pZ₃, as a control. Independent transformants were shake flask cultured in minimal YNB medium with 2% w/V Glucose as a carbon source (+0.67 % w/V YNB and aa, according to the manufacturer's protocol) till mid-exp phase (also referred to as mid-log). The β-glucoamylase activity was determined as follows: after cell density determination, the cells were harvested in order to rescue the culture supernatant. 15µl/ml 3M NaAc, pH 5.2 and 20 µl/ml 1% w/V Starch (Fluka 85642 - high solubility -) were added. Subsequently, the samples were mixed well and incubated at the desired temperature (this experiment: 50°C). At time zero and every following 20 min, 1 ml of the incubated medium is taken, ice-cooled for 2 min, 50µl of Lugol solution (Fluka 62650) were added, shaken quickly and read at the spectrophotometer at λ580 nm. The slope of the resulting values corresponds to the glucoamylase activity. Fig. 8 shows the glucoamylase activity of three independent clones expressing the GAA and one negative control. The enzymatic activity is expressed in mU/OD, and it is calculated considering that 1U corresponds to the variation of 1 OD in 1 min. The values reported in the graphic were subtracted of the basic activity level of *Z. bailii*, as measured in the control sample.

25 *Z. bailii* and *S. cerevisiae* cells were transformed (according to Example 2) with the plasmids pZ₃STA2 and pZ₃klSTA2, and with the empty plasmid pZ₃, as a control. Independent transformants were shake flask cultured in minimal YNB medium with 2% w/V fructose as a carbon source (+0.67 % w/V YNB and aa, according to the manufacturer's protocol) till mid-exp phase (also referred to as mid-log). The α-glucoamylase activity was determined according to the literature (Modena *et al.*, 1986, Arch of Biochem. And Biophys. 248, 138-50) as follows:

after cell density determination, the cells were harvested in order to rescue the culture supernatant, and an aliquot of said supernatant is used for preparing the following reaction mix:

Supernatant	100µl
5 Maltotriose 400mM	6.3µl
NaAc 200mM pH 4.6	125µl
H ₂ O	18.7µl
total	250µl

The mix is incubated for 1 hour at 37°C under slow agitation, and after that time
10 an aliquot of said mixture is used to evaluate the reaction. The product of maltotriose degradation is glucose, and its concentration can be determined using a commercially available enzymatic kit from Boehringer Mannheim GmbH, Germany (Cat # 716251). 1U of glucoamylase specific activity is the quantity of enzyme necessary to release 1 µmol min-1 of glucose in said condition.

15

Example 6: Expression of β-galactosidase (β-gal) in *Z. bailii*

Z. bailii cells were transformed (according to Example 2) with the plasmid pZ₃LacZ (Fig. 3b), with the plasmid pZ₃bTLacZ (Fig. 4b), with the plasmid pZ₃rGLacZ, and with the empty plasmid pZ₃, as a control. Independent
20 transformants were shake flask cultured in YPD medium (see description above) with 2% w/V Glucose as a carbon source till mid-exp phase. β-galactosidase activity determination: after cell density determination, 1 ml culture is harvested into an eppendorf tube, spun for 5 minutes (to get a hard pellet), aspirated with a pipet, (not using the vacuum line!), washed in 1 ml Z buffer [w/o BME - betamercaptoethanol -; Z buffer: 16.1g/l Na₂HPO₄.7H₂O, 5.5g/l NaH₂PO₄.H₂O, 0.75g/l KCl, 0.246g/l MgSO₄.7H₂O], repelleted, suspended in 150µl Z buffer (with BME, 27µl/10ml), 50µl chloroform are added, 20µl 0.1% SDS and vortexed
25 vigorously for 15''. 700µl of pre-warmed ONPG (o-nitrophenyl β-D-galactopyranoside, Sigma N-1127, 1 mg/ml in Z+BME) are added, and the reaction is started at 30°C (20' to 3hr), checking the time. When the suspension turns yellow the reaction is stopped by addition of 0.5 ml of 1 M NaCO₃; after
30

centrifugation for 10 min at maximum speed the sample is read at the spectrophotometer at λ 420.

Fig. 8b shows the β -gal activity of three independent clones expressing the β -gal under control of the *Z. bailii TPI* promoter, two independent clones expressing the *β-gal* under control of the *S. cerevisiae TPI* promoter and one negative control (see the legend of the figure for indications of the respective clones). The enzymatic activity is expressed as Miller Unit/OD and it is calculated according to the following formula:

$$10 \quad \text{Miller Units} = \frac{A_{420} \times 1000}{A_{660} \times \text{time (min)} \times \text{Vol (ml)}}$$

As it is readily visible, the expression from the endogenous TPI promoter is much stronger (4-5 times) than from the respective promoter from *S. cerevisiae*.

A similar series of experiments was performed in order to evaluate the efficiency of the plasmids based on the sequences of the endogenous *Z. bailii* plasmid in improving the expression levels of heterologous proteins. *Z. bailii* cells were transformed (according to Example 2) with the following plasmids: pZ₃LacZ (Fig. 3b), p195LacZ, pEZ-IALacZ, pEZ-IAFLacZ, pEZ₂LacZ and pEZ₂-IBLacZ. Independent transformants were grown till mid-log phase and β -galactosidase activity measured, as previously described. The corresponding data are reported in Fig. 10b.

Example 7: Isolation of an endogenous *Z. bailii* plasmid

Z. bailii strains ATCC 36947 and NCYC 1427 were cultivated and their endogenous plasmid was extracted, resulting in the plasmids pZB₁ and pZB₅ (see Figs. 9 a and b). The protocol used was a modification of a protocol by Lorincz, A., 1985, BRL Focus 6, 11, and uses glass beads to break the cells. After the DNA extraction, samples were loaded on an agarose gel and the band corresponding to the plasmid was eluted (Qiagen, QIAquick Gel Extraction Kit cat n° 28704).

30 The plasmid extracted from NCYC 1427 was cut with EcoRI and some of the fragments were sequenced. These sequences correspond to SEQ ID No.: 63, SEQ

ID No.: 64, SEQ ID No.: 65, SEQ ID No.: 66, SEQ ID No.: 67, SEQ ID No.: 68, SEQ ID No.: 69 or SEQ ID No.: 70, respectively.

Example 8: Sequence amplification of the open reading frames and of structural

5 sequences of the endogenous *Z. bailii* plasmids

The genomic DNA extracted from the *Z. bailii* strains ATCC 36947 and NCYC 1427 were used as a template for the amplification of the open reading frames and of structural sequences of the endogenous *Z. bailii* plasmids.

The oligos for the amplification are the following:

10 *5FLP* (SEQ ID NO.: 84)

5'-TAGCTACTCTTCTCCAGGTGTCATTAG-3' Tm: 63.4

3FLP (SEQ ID NO.: 85)

5'-CCTATGTCCGAGTTAGCGAGCTTG-3' Tm: 64.6

5TFC (SEQ ID NO.: 86)

15 5'-AGAATGAACTCAGAGTTCTCTCTTG-3'

Tm: 59.7

3TFC (SEQ ID NO.: 87)

5'-ATTCTATTGGGTATGTCCCCTG-3' Tm: 58.4

5TFB (SEQ ID NO.: 88)

5'-GTTTTAACATTGAAGCTCACCTTAATTG-3' Tm: 58.6

20 *3TFB* (SEQ ID NO.: 89)

5'-ATTATGTTCTCCAGGGAAGAGGTTAG-3' Tm: 61.6

5IRAARS (SEQ ID NO.: 90)

5'-AGAATCAATCATTTAGTGTGGCAGGAG-3' Tm: 61.9

3IRAARS (SEQ ID NO.: 91)

25 5'-AAAAAACTGCCGCCATATTCGTC-3'

Tm: 61.3

The following program was used for the amplification:

94°C	5min	
94°C	15s	}
58°C	30s	} 25 cycles
72°C	2min	J

72°C	7min
4°C	∞

The amplified fragments, sub-cloned into the vector pST-Blue1 (Novagen, Perfect Blunt cloning Kit cat. no. 70191-4), were sequenced and correspond to SEQ ID No.: 71 (IR-ARS), SEQ ID No.: 72 (FLP), SEQ ID No.: 74 (TFB) and SEQ ID No.: 76 (TFC), respectively.

These coding sequences are used for the construction of the expression plasmid pEZ₁, according to Figure 9b.

Example 9: Construction of expression plasmids based on replication and

10 stability sequences from the *Z. bailii* pSB2 plasmid

The backbone of the new vectors is the basic *S. cerevisiae* multicopy plasmid Yeplac 195 (Gietz and Sugino, 1988, Gene 74, 527-34) modified to the expression plasmid pBR195, as described in Branduardi (2002, Yeast 19, 1165-70).

For the construction of the plasmid p195, the plasmid pBR195 was cut AatII/ApaI-blunt in order to excise the URA marker and the Kan^R cassette, excised SphI/SacI-blunt from pFA6-KanMX4 (Wach *et al.*, 1994 Yeast 10, 1793-1808) was here inserted. From this plasmid derives the plasmid p195LacZ: the LacZ gene was sub-cloned from the plasmid pZ₃LacZ cut SphI/NheI into the new plasmid p195, opened with the same enzymes.

20 For the construction of the plasmids pEZ-IA and pEZ-IALacZ, the plasmids p195 and p195LacZ were opened NaiI/StuI-blunt, in order to remove the *S. cerevisiae* 2μm-ori. The PCR fragment corresponding to the IR-A and ARS sequence from the pSB2 (see previous example for amplification detail) was excised EcoRI-blunt from the pST-Blue1 plasmid and sub-cloned into the opened vectors just described.

25 For the construction of the plasmid pEZ-IAFLacZ, the plasmid pEZ-IALacZ was SmaI opened, and there the fragment corresponding to the FLP and the sequence containing its promoter, derived from the pST-Blue1 plasmid opened Acc1-

blunt/SnaBI, was there sub-cloned. Said sequence was PCR amplified from the genomic DNA extracted from the *Z. bailii* strains ATCC 36947.

The oligos for the amplification are the following:

pFLP (SEQ ID NO.: 95)

5' ACGCAAGAGAGAACTCTGAGTCAT-3' Tm: 61.3

3FLP (SEQ ID NO.: 85)

5'-CCTATGTCCGAGTTAGCGAGCTTG-3' Tm: 64.6

The following program was used for the amplification:

94°C	5min	
94°C	15s	}
58°C	30s	} 29 cycles
72°C	1min 30s	J
72°C	7min	
4°C	∞	

For the construction of the plasmids pEZ₂ and pEZ₂LacZ, the plasmids pEZ-IA and pEZ-IALacZ were opened SmaI and the PCR fragment corresponding to the sequences of FLP and TFC and the respective promoters was excised SnaBI/SalI-

5 blunt from the pST-Blue1 plasmid and sub-cloned into the opened vectors just described.

The oligos for the amplification are the following:

5FLP (SEQ ID NO.: 84)

5'-TAGCTACTCTTCTCCAGGTGTCATTAG-3' Tm: 63.4

10 3TFC (SEQ ID NO.: 87)

5'-ATTCTATTGGGTATGTCCCCTG-3' Tm: 58.4

The following program was used for the amplification:

94°C	5min	
94°C	15s	}
58°C	30s	} 25 cycles
72°C	1min 30s	J
72°C	7min	
4°C	∞	

For resulting in the plasmid pEZ₂ an additional cloning step was required, in order

15 to re-insert the polyA: the polyA was excised NaeI/NheI-blunt from the plasmid pYX022 and was sub-cloned in the transitory plasmid BamHI-blunt and de-phosphorylated.

For the construction of the plasmid pEZ₂-IBLacZ, the plasmid pEZ2LacZ was opened SalI-blunt and de-phosphorylated, and the fragment IR-B was therein sub-

cloned. That fragment was EcoRI-blunt extracted from pST-Blue1 (see previous example).

Example 10: Plasmid stability determination

- 5 The stability of the plasmids described in the previous example was determined as follows: independent *Z. bailii* transformants bearing the different plasmids were inoculated at a cellular density of 5×10^3 cells/ml in rich media (YPD) and in rich selective media (YPD + G418), respectively. At T_0 of the inoculum and then after 10 and 20 generations, 500 cells from any culture were plated 3 times on selective 10 and non-selective agar plates, and subsequently incubated at 30°C till the colonies became visible. The ratio between the mean of the colony number grown on selective medium and the mean of the colony number grown on non selective medium gives the percentage of mitotic stability.

Claims:

1. Process for the production of a protein comprising
 - a) culturing a *Zygosaccharomyces bailii* strain
 - b) expressing and secreting the protein
 - c) isolating the protein.
2. The process of claim 1, wherein the *Z. bailii* strain is transformed with a vector comprising a DNA sequence coding for the protein, functionally linked to a signal sequence leading to the secretion of the protein and further functionally linked to a promoter.
3. The process of claim 2, wherein the vector is an extra-chromosomal plasmid.
4. The process of claim 3, wherein the plasmid is derived from an endogenous episomal plasmid from a *Z. bailii* strain.
5. The process of claim 2, wherein the plasmid comprises sequences for replication, stabilization and/or plasmid copy number control, obtainable from *Z. bailii*.
6. The process of claim 4, wherein the plasmid comprises at least 35 bases of one of the sequences selected from the list of: SEQ ID No.: 63, SEQ ID No.: 64, SEQ ID No.: 65, SEQ ID No.: 66, SEQ ID No.: 67, SEQ ID No.: 68, SEQ ID No.: 69, SEQ ID No.: 70 or SEQ ID No.: 71.
7. The process of claims 2-6, wherein the promoter is a triose-phosphate isomerase promoter, obtainable from *Saccharomyces cerevisiae* or from *Z. bailii*, preferably from *Z. bailii*.
8. The process of claims 2-6, wherein the promoter is a glyceraldehyde phosphate dehydrogenase promoter, obtainable from *Saccharomyces cerevisiae*, *Z. bailii* or *Z. rouxii*, preferably from *Z. rouxii*.
9. The process of claims 2-8, wherein the signal sequence is a continuous stretch of 15 to 60 amino acids, comprising one or more positively charged amino

acid(s) followed by a stretch of about 5 to 10 hydrophobic amino acids, which may or may not be interrupted by non-hydrophobic residues.

10. The process of claims 2-8, wherein the signal sequence is selected from the list of: SEQ ID NO.: 1, SEQ ID NO.: 3, SEQ ID NO.: 5, SEQ ID NO.: 7, SEQ ID NO.: 9, SEQ ID NO.: 11, SEQ ID NO.: 13, SEQ ID NO.: 15, SEQ ID NO.: 17, SEQ ID NO.: 19, SEQ ID NO.: 21, SEQ ID NO.: 23, SEQ ID NO.: 25, SEQ ID NO.: 27, SEQ ID NO.: 29, SEQ ID NO.: 31, SEQ ID NO.: 33, SEQ ID NO.: 35, SEQ ID NO.: 37, SEQ ID NO.: 39, SEQ ID NO.: 41, SEQ ID NO.: 43, SEQ ID NO.: 45, SEQ ID NO.: 47, SEQ ID NO.: 49, SEQ ID NO.: 51, SEQ ID NO.: 53, SEQ ID NO.: 55, SEQ ID NO.: 57, SEQ ID NO.: 59, SEQ ID NO.: 61.
11. The process of claim 1, wherein the *Z. bailii* strain is transformed with a vector comprising the DNA sequence coding for the protein, functionally linked to the signalling pre-sequence of the alpha-subunit of the K1 killer toxin of *Kluyveromyces lactis* and further functionally linked to the triose-phosphate isomerase promoter from *S. cerevisiae*.
12. The process of claim 11, wherein the vector is the plasmid pZ₃kl as shown in figure 1 b.
13. The process of claim 1, wherein the *Z. bailii* strain is transformed with a vector comprising the DNA sequence coding for the protein, functionally linked to the signal sequence of the pre-pro α -factor of *S. cerevisiae* and further functionally linked to the triose-phosphate isomerase promoter from *S. cerevisiae*.
14. The process of claim 13, wherein the vector is the plasmid pZ₃pp α as shown in figure 1 c.
15. The process of claims 2-14, wherein the DNA sequence coding for the protein is derived from animal, bacterial, fungal, plant or viral sources.
16. The process of claims 2-15, wherein the *Z. bailii* strain that is transformed is selected from the list of: ATCC 36947, ATCC 60483, NCYC 1427 or ATCC 8766.

17. The process of one of the preceding claims, wherein the *Z. bailii* strain has been subjected to a selection process for improved secretion.
18. The process of one of the preceding claims, wherein the *Z. bailii* strain is cultivated in a chemically defined medium.
19. The process of one of the preceding claims, wherein the protein is isolated from the culture medium.
20. A *Z. bailii* strain, expressing and secreting a heterologous protein.
21. The *Z. bailii* strain of claim 20, wherein the cells are transformed with a vector comprising a DNA sequence coding for the heterologous protein, functionally linked to a signal sequence leading to the secretion of the protein and further functionally linked to a promoter.

Figure 1






**a****b****c**


Figure 2



a



b



c

Figure 3



**a****b**



Figure 4









Figure 5**YNB Glc 5%****YPD Glc 5%****a****YNB Glc 5%****YPD Glc 5%****b****c****d**

Figure 6





Figure 7







Figure 8

Glucoamylase activity






a



b



9/12

Figure 9





10/12

Figure 10




11/12

Figure 11



12/12

Figure 12



p779.ST25
SEQUENCE LISTING

-
<110> Porro, Danilo

<120> Process for expression and secretion of proteins by the non-conventional yeast *Zygosaccharomyces bailii*

<130> p 779wo

<150> DE 10252245.6
<151> 2003-11-07

<160> 95

<170> PatentIn version 3.1

<210> 1
<211> 57
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>
<221> sig_peptide
<222> (1)..(57)
<223>

<400> 1
cgacagtaaa ttttgcgaa tttaatagct tctactgaaa aacagtggac catgtga 57

<210> 2
<211> 19
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> SIGNAL
<222> (1)..(19)

p779.ST25

<223>

<400> 2

Met	Arg	Phe	Pro	Ser	Ile	Phe	Thr	Ala	Val	Leu	Phe	Ala	Ala	Ser	Ser
1					5				10					15	

Ala Leu Ala

<210> 3

<211> 255

<212> DNA

<213> *Saccharomyces cerevisiae*

<220>

<221> sig_peptide

<222> (1)..(255)

<223>

<400> 3

cgacagtaaa	ttttgccgaa	ttaatagct	tctactgaaa	aacagtggac	catgtgaaaa	60
gatgcatctc	atttatcaaa	cacataatat	tcaagtggac	cttacttcaa	ttgtattgaa	120
gtgcaagaaa	accaaaaagc	aacaacaggt	tttggataag	tacatatata	agagggcctt	180
ttgttccat	caaaaatgtt	actgttctta	cgattcattt	acgattcaag	aatagttcaa	240
acaagaagat	tacaa					255

<210> 4

<211> 85

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> SIGNAL

<222> (1)..(85)

<223>

<220>

p779.ST25

<221> PROPEP

<222> (20) .. (85)

<223>

<400> 4

Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser
1 5 10 15

Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln
20 25 30

Ile Pro Ala Glu Ala Val Ile Gly Tyr Leu Asp Leu Glu Gly Asp Phe
35 40 45

Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu
50 55 60

Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val
65 70 75 80

Ser Leu Asp Lys Arg
85

<210> 5

<211> 63

<212> DNA

<213> Aspergillus niger

<220>

<221> sig_peptide

<222> (1)..(63)

<223>

<400> 5
atgatggtcg cgtggtggtc tctatttctg tacggcccttc aggtcgcgac acctgctttg 60
gct 63

<210> 6

<211> 21

<212> PRT

<213> Aspergillus niger

p779.ST25

<220>

<221> SIGNAL

<222> (1)..(21)

<223>

<400> 6

Met Met Val Ala Trp Trp Ser Leu Phe Leu Tyr Gly Leu Gln Val Ala
1 5 10 15

Ala Pro Ala Leu Ala
20

<210> 7

<211> 93

<212> DNA

<213> *Bacillus* sp.

<220>

<221> sig_peptide

<222> (1)..(93)

<223>

<400> 7

atgcaaaaca cagcgaaaaa ctccatctgg cagagggtgc gccacagcgc cattgcctta 60

tccgctctca gtttatcctt tggcctgcag gcc 93

<210> 8

<211> 31

<212> PRT

<213> *Bacillus* sp.

<220>

<221> SIGNAL

<222> (1)..(31)

<223>

p779.ST25

<400> 8

Met Gln Asn Thr Ala Lys Asn Ser Ile Trp Gln Arg Val Arg His Ser
1 5 10 15

Ala Ile Ala Leu Ser Ala Leu Ser Leu Ser Phe Gly Leu Gln Ala
20 25 30

<210> 9

<211> 63

<212> DNA

<213> Aspergillus oryzae

<220>

<221> sig_peptide

<222> (1)..(63)

<223>

<400> 9

atgcagtcca tcaagcgtac cttgctcctc ctcggagcta tccttccgc ggtcctcggt 60

gcc 63

<210> 10

<211> 21

<212> PRT

<213> Aspergillus oryzae

<220>

<221> SIGNAL

<222> (1)..(21)

<223>

<400> 10

Met Gln Ser Ile Lys Arg Thr Leu Leu Leu Leu Gly Ala Ile Leu Pro
1 5 10 15

Ala Val Leu Gly Ala
20

<210> 11

p779.ST25

<211> 75

<212> DNA

<213> *Bacillus amyloliquefaciens*

<220>

<221> sig_peptide

<222> (1)..(75)

<223>

<400> 11
atgaaacgag tgttgctaat tcttgtcacc ggattgtta tgagtttgc tgggatcact 60
tcttagtgttt cggct 75

<210> 12

<211> 25

<212> PRT

<213> *Bacillus amyloliquefaciens*

<220>

<221> SIGNAL

<222> (1)..(25)

<223>

<400> 12

Met Lys Arg Val Leu Leu Ile Leu Val Thr Gly Leu Phe Met Ser Leu
1 5 10 15

Cys Gly Ile Thr Ser Ser Val Ser Ala
20 25

<210> 13

<211> 51

<212> DNA

<213> *Saccharomyces fibuligera*

<220>

<221> sig_peptide

p779.ST25

<222> (1)..(51)

<223>

<400> 13
atgttcatga tagtacagct tttggcttt gcactaggcc ttgctgttgc t

51

<210> 14

<211> 17

<212> PRT

<213> *Saccharomyces fibuligera*

<220>

<221> SIGNAL

<222> (1)..(17)

<223>

<400> 14

Met Leu Met Ile Val Gln Leu Leu Val Phe Ala Leu Gly Leu Ala Val
1 5 10 15

Ala

<210> 15

<211> 51

<212> DNA

<213> *Saccharomyces fibuligera*

<220>

<221> sig_peptide

<222> (1)..(51)

<223>

<400> 15
atgttcatga ttttggaaact ctttagtactt attataggcc ttggagttgc t

51

<210> 16

<211> 17

p779.ST25

<212> PRT

<213> *Saccharomyces fibuligera*

<220>

<221> SIGNAL

<222> (1)..(17)

<223>

<400> 16

Met	Leu	Leu	Ile	Leu	Glu	Leu	Leu	Val	Leu	Ile	Ile	Gly	Leu	Gly	Val
1				5				10					15		

Ala

<210> 17

<211> 66

<212> DNA

<213> *Hypocrea pecorina*

<220>

<221> sig_peptide

<222> (1)..(66)

<223>

<400> 17

atggcgccct cagttacact gccgttgacc acggccatcc tggccattgc ccggctcgtc 60

gccgcc 66

<210> 18

<211> 22

<212> PRT

<213> *Hypocrea pecorina*

<220>

<221> SIGNAL

<222> (1)..(22)

p779.ST25

<223>

<400> 18

Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala Ile Leu Ala Ile
1 5 10 15

Ala Arg Leu Val Ala Ala
20

<210> 19

<211> 63

<212> DNA

<213> Hypocrea pecorina

<220>

<221> sig_peptide

<222> (1)..(63)

<223>

<400> 19

atgaacaagt ccgtggctcc attgctgctt gcagcgtcca tactatatgg cggcgccgtc 60
gca 63

<210> 20

<211> 21

<212> PRT

<213> Hypocrea pecorina

<220>

<221> SIGNAL

<222> (1)..(21)

<223>

<400> 20

Met Asn Lys Ser Val Ala Pro Leu Leu Leu Ala Ala Ser Ile Leu Tyr
1 5 10 15

Gly Gly Ala Val Ala
20

p779.ST25

<210> 21
<211> 48
<212> DNA
<213> *Arxula adeninivorans*

<220>
<221> sig_peptide
<222> (1)..(48)
<223>

<400> 21 atgcgtcagt ttcttagcact tgctgctgct gcttccatag cgggtggca 48

<210> 22
<211> 18
<212> PRT
<213> *Arxula adeninivorans*

<220>
<221> SIGNAL
<222> (1)..(18)
<223>

<400> 22
Met Arg Gln Phe Leu Ala Leu Ala Ala Ala Ala Ser Ile Ala Val Ala
1 5 10 15

Asp Ser

<210> 23
<211> 57
<212> DNA
<213> *Homo sapiens*

<220>

p779.ST25

<221> sig_peptide
<222> (1)..(57)
<223>

<400> 23
atgcagcgac tatgtgtgta tgtgctgatc tttgcactgg ctctggccgc cttctct 57

<210> 24
<211> 19
<212> PRT
<213> Homo sapiens

<220>
<221> SIGNAL
<222> (1)..(19)
<223>

<400> 24
Met Gln Arg Leu Cys Val Tyr Val Leu Ile Phe Ala Leu Ala Leu Ala
1 5 10 15
Ala Phe Ser

<210> 25
<211> 75
<212> DNA
<213> Rhizopus oryzae

<220>
<221> sig_peptide
<222> (1)..(75)
<223>

<400> 25
atgcaactgt tcaatttgcc attgaaagtt tcattcttc tcgtcctctc ttactttct 60
ttgctcgaaa ctgct 75

p779.ST25

<210> 26
<211> 25
<212> PRT
<213> *Rhizopus oryzae*

<220>
<221> SIGNAL
<222> (1)..(25)
<223>

<400> 26
Met Gln Leu Phe Asn Leu Pro Leu Lys Val Ser Phe Phe Leu Val Leu
1 5 10 15

Ser Tyr Phe Ser Leu Leu Val Ser Ala
20 25

<210> 27
<211> 48
<212> DNA
<213> *Aspergillus niger*

<220>
<221> sig_peptide
<222> (1)..(48)
<223>

<400> 27
atgcagactc tccttgtag ctcgcttgt gtctccctcg ctgcggcc 48

<210> 28
<211> 16
<212> PRT
<213> *Aspergillus niger*

<220>
<221> SIGNAL

p779.ST25

<222> (1)..(16)

<223>

<400> 28

Met Gln Thr Leu Leu Val Ser Ser Leu Val Val Ser Leu Ala Ala Ala
1 5 10 15

<210> 29

<211> 54

<212> DNA

<213> Homo sapiens

<220>

<221> sig_peptide

<222> (1)..(54)

<223>

<400> 29

atgaagtggg taacctttat ttcccttctt tttctctta gctcggctta ttcc 54

<210> 30

<211> 18

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)..(18)

<223>

<400> 30

Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
1 5 10 15

Tyr Ser

<210> 31

p779.ST25

<211> 78

<212> DNA

<213> *Saccharomyces cerevisiae*

<220>

<221> sig_peptide

<222> (1)..(78)

<223>

<400> 31
atgacgaagc caaccagaat attagttaga tccgtcagta tattatTTTt catcacatta 60
ctacacctag tcgttagcg 78

<210> 32

<211> 26

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> SIGNAL

<222> (1)..(26)

<223>

<400> 32

Met Thr Lys Pro Thr Gln Val Leu Val Arg Ser Val Ser Ile Leu Phe
1 5 10 15

Phe Ile Thr Leu Leu His Leu Val Val Ala
20 25

<210> 33

<211> 63

<212> DNA

<213> *Saccharomyces cerevisiae*

<220>

<221> sig_peptide

p779.ST25

<222> (1)..(63)

<223>

<400> 33
atgggccact tagcgatcct tttcagtatt atcgctgtat tgaatatagc tacagctgtt 60

gca 63

<210> 34

<211> 21

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> SIGNAL

<222> (1)..(21)

<223>

<400> 34

Met Gly His Leu Ala Ile Leu Phe Ser Ile Ile Ala Val Leu Asn Ile
1 5 10 15

Ala Thr Ala Val Ala
20

<210> 35

<211> 48

<212> DNA

<213> *Kluyveromyces lactis*

<220>

<221> sig_peptide

<222> (1)..(48)

<223>

<400> 35
ataaaaatgaa tatattttac atattttgtt ttttgctgtc attcggttc 48

<210> 36

p779.ST25

<211> 17

<212> PRT

<213> *Kluyveromyces lactis*

<220>

<221> SIGNAL

<222> (1)..(17)

<223>

<400> 36

Met	Asn	Ile	Phe	Tyr	Ile	Phe	Leu	Phe	Leu	Leu	Ser	Phe	Val	Gln	Gly
1				5				10						15	

Leu

<210> 37

<211> 69

<212> DNA

<213> *Kluyveromyces lactis*

<220>

<221> sig_peptide

<222> (1)..(69)

<223>

<400> 37

ataaaaatgaa tatattttac atattttgt ttttgctgtc attcggttcaa ggtttggagc 60

ataactcatc 69

<210> 38

<211> 23

<212> PRT

<213> *Kluyveromyces lactis*

<220>

<221> SIGNAL

p779.ST25

<222> (1)..(23)

<223>

<400> 38

Met Lys Ile Tyr His Ile Phe Ser Val Cys Tyr Leu Ile Thr Leu Cys
1 5 10 15

Ala Ala Ala Ala Thr Thr Ala
20

<210> 39

<211> 54

<212> DNA

<213> *Saccharomyces cerevisiae*

<220>

<221> sig_peptide

<222> (1)..(54)

<223>

<400> 39

atgttgctt tctactttct caccgcatgc atcagttga agggcgttt tggg 54

<210> 40

<211> 18

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> SIGNAL

<222> (1)..(18)

<223>

<400> 40

Met Phe Ala Phe Tyr Phe Leu Thr Ala Cys Ile Ser Leu Lys Gly Val
1 5 10 15

Phe Gly

p779.ST25

<210> 41
<211> 54
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>
<221> sig_peptide
<222> (1)..(54)
<223>

<400> 41
atgtttaagt ctgttgtta ttcggttcta gccgctgctt tagttaatgc aggt 54

<210> 42
<211> 18
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> SIGNAL
<222> (1)..(18)
<223>

<400> 42
Met Phe Lys Ser Val Val Tyr Ser Val Leu Ala Ala Ala Leu Val Asn
1 5 10 15

Ala Gly

<210> 43
<211> 51
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>

p779.ST25

<221> sig_peptide
<222> (1)..(51)
<223>

<400> 43 atgtttaaat ctgttgttta ttcaatttta gccgcttc tt tgccaatgc a 51

<210> 44
<211> 17
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>

<221> SIGNAL
<222> (1)..(17)
<223>

<400> 44
Met Phe Lys Ser Val Val Tyr Ser Ile Leu Ala Ala Ser Leu Ala Asn
1 5 10 15

Ala

<210> 45
<211> 48
<212> DNA
<213> *Kluyveromyces lactis*

<220>
<221> sig_peptide
<222> (1)..(48)
<223>

<400> 45 atgcttatcta ttctgttag tttattatca ttatcaggga cccatgcg 48

<210> 46

p779.ST25

<211> 16

<212> PRT

<213> *Kluyveromyces lactis*

<220>

<221> SIGNAL

<222> (1)..(16)

<223>

<400> 46

Met Leu Ser Ile Leu Leu Ser Leu Leu Ser Leu Ser Gly Thr His Ala
1 5 10 15

<210> 47

<211> 48

<212> DNA

<213> *Kluyveromyces lactis*

<220>

<221> sig_peptide

<222> (1)..(48)

<223>

<400> 47

atgctatatcta ttctgttggg tttatttatca ctatcaggga cccatgcg

48

<210> 48

<211> 16

<212> PRT

<213> *Kluyveromyces lactis*

<220>

<221> SIGNAL

<222> (1)..(16)

<223>

p779.ST25

<400> 48

Met Leu Ser Ile Leu Leu Gly Leu Leu Ser Leu Ser Gly Thr His Ala
1 5 10 15

<210> 49

<211> 54

<212> DNA

<213> Aspergillus niger

<220>

<221> sig_peptide

<222> (1)..(54)

<223>

<400> 49

atgggcgtct ctgctgttct acttcctttg tatctcctgt ctggagtcac ctcc 54

<210> 50

<211> 18

<212> PRT

<213> Aspergillus niger

<220>

<221> SIGNAL

<222> (1)..(18)

<223>

<400> 50

Met Gly Val Ser Ala Val Leu Leu Pro Leu Tyr Leu Leu Ser Gly Val
1 5 10 15

Thr Ser

<210> 51

<211> 57

<212> DNA

<213> Saccharomyces cerevisiae

p779.ST25

<220>

<221> sig_peptide

<222> (1)..(57)

<223>

<400> 51
atgctttgc aagcttcct tttcctttg gctggtttg cagccaaat atctgca 57

<210> 52

<211> 19

<212> PRT

<213> Saccharomyces cerevisiae

<220>

<221> SIGNAL

<222> (1)..(19)

<223>

<400> 52

Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
1 5 10 15

Ile Ser Ala

<210> 53

<211> 63

<212> DNA

<213> Saccharomyces cerevisiae

<220>

<221> sig_peptide

<222> (1)..(63)

<223>

<400> 53
atgcaaagac catttctact cgcttatttg gtccttcac ttctatcaa ctgggtttg 60

p779.ST25

ggt

63

<210> 54
<211> 21
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> SIGNAL
<222> (1)..(21)
<223>

<400> 54
Met Gln Arg Pro Phe Leu Leu Ala Tyr Leu Val Leu Ser Leu Leu Phe
1 5 10 15
Asn Ser Ala Leu Gly
20

<210> 55
<211> 63
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>
<221> sig_peptide
<222> (1)..(63)
<223>

<400> 55
atgcaaagac catttctact cgcttatttg gtccttcgc ttctatttaa ctcagctttg 60
ggt 63

<210> 56
<211> 21
<212> PRT
<213> *Saccharomyces cerevisiae*

p779.ST25

<220>

<221> SIGNAL

<222> (1)..(21)

<223>

<400> 56

Met	Gln	Arg	Pro	Phe	Leu	Leu	Ala	Tyr	Leu	Val	Leu	Ser	Leu	Leu	Phe
1				5					10					15	

Asn	Ser	Ala	Leu	Gly
		20		

<210> 57

<211> 96

<212> DNA

<213> *Saccharomyces cerevisiae*

<220>

<221> sig_peptide

<222> (1)..(96)

<223>

<400> 57

atggtaggcc tcaaaaatcc atatacgcac actatgcaa gaccatttct actcgcttat 60

ttggtccttt cgttctatt taactcagct ttgggt 96

<210> 58

<211> 32

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> SIGNAL

<222> (1)..(32)

<223>

p779.ST25

<400> 58

Met Val Gly Leu Lys Asn Pro Tyr Thr His Thr Met Gln Arg Pro Phe
1 5 10 15

Leu Leu Ala Tyr Leu Val Leu Ser Leu Leu Phe Asn Ser Ala Leu Gly
20 25 30

<210> 59

<211> 63

<212> DNA

<213> Zygosaccharomyces bailii

<220>

<221> sig_peptide

<222> (1)..(63)

<223>

<400> 59

atgaaagcag cccaaatatt aacagcaagt atagtaagct tattgccaat atataactagt 60

gct 63

<210> 60

<211> 21

<212> PRT

<213> Zygosaccharomyces bailii

<220>

<221> SIGNAL

<222> (1)..(21)

<223>

<400> 60

Met Lys Ala Ala Gln Ile Leu Thr Ala Ser Ile Val Ser Leu Leu Pro
1 5 10 15

Ile Tyr Thr Ser Ala
20

<210> 61

p779.ST25

<211> 417

<212> DNA

<213> *Zygosaccharomyces bailii*

<220>

<221> sig_peptide

<222> (1)..(417)

<223>

<400> 61	
atgaaaaggcag cccaaatatt aacagcaagt atagtaagct tattgccaat atataactagt	60
gcttagaaaca tattagacag agaatacaca gcaaacgaat taaaaactgc ttttggagat	120
gaagaaattt ttacagattt gacgtatcac attcacgtta acgtcagtgg cgaaattgac	180
tcttactatc ataattttgtt caatttgtc gataacgctc tagcaaacaa agatattaat	240
agatataatat acgcttatatt tacacagcag acaaactata cagaggatgg gctcattgag	300
tacttaaatc attacgattc agagacttgc aaagatatca ttactcagta taatgttaac	360
gtagacacta gtaactgtat aagcaatact acagatcaag ctagactcca acgtcgc	417

<210> 62

<211> 139

<212> PRT

<213> *Zygosaccharomyces bailii*

<220>

<221> SIGNAL

<222> (1)..(139)

<223>

<220>

<221> PROPEP

<222> (22)..(139)

<223>

<400> 62

Met Lys Ala Ala Gln Ile Leu Thr Ala Ser Ile Val Ser Leu Leu Pro	
1	5
10	
15	

p779.ST25

Ile Tyr Thr Ser Ala Arg Asn Ile Leu Asp Arg Glu Tyr Thr Ala Asn
 20 25 30

Glu Leu Lys Thr Ala Phe Gly Asp Glu Glu Ile Phe Thr Asp Leu Thr
 35 40 45

Tyr His Ile His Val Asn Val Ser Gly Glu Ile Asp Ser Tyr Tyr His
 50 55 60

Asn Leu Val Asn Phe Val Asp Asn Ala Leu Ala Asn Lys Asp Ile Asn
 65 70 75 80

Arg Tyr Ile Tyr Ala Ile Phe Thr Gln Gln Thr Asn Tyr Thr Glu Asp
 85 90 95

Gly Leu Ile Glu Tyr Leu Asn His Tyr Asp Ser Glu Thr Cys Lys Asp
 100 105 110

Ile Ile Thr Gln Tyr Asn Val Asn Val Asp Thr Ser Asn Cys Ile Ser
 115 120 125

Asn Thr Thr Asp Gln Ala Arg Leu Gln Arg Arg
 130 135

<210> 63

<211> 587

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 63		
tttagatct aaaaataaat aatataaatt acctcatcca gagtcccccc ccaaatcctt	60	
attctaaata ataagctact cctccccccc caggagtatt tttaggggga ggggggacct	120	
taactcaagg gggagtagtt ttgaggatca catggaaagt atttaataaa atagtagttc	180	
ttttgttta aaaaggcctc tccaaaagta atacttttag ggttaattact aagtataata	240	
tatattataa gtaatagcct ttatagctta atggtaaagc agtaaattga agatttacct	300	
atatgttagtt cgattctcat taagggcaat ataaataagc ttttaatgg gccaatagct	360	
gaaataagta atattattgt aaatatttgag acttgaactc aaatcttatg cacctaaaaa	420	
catatatttt aaccaattaa attatattta ctttattatt tacttatata acttctacta	480	
attgtaaagt ataaccagct ttttgttaa caacaaaaac cgagagggtt catgttatat	540	
ataatttata attgttctta ctttatttat aaaagaataa ccgaatg	587	

<210> 64

p779.ST25

<211> 435

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 64	
ttaatttaat ttgtcgctaa ataataatgt tttaaatattt ataaatattt caaccaacca	60
cccccccaa aagggggtgg ttggtggtt gtcgtcacca accaccttg gtgggtggtg	120
ccccctatga gtttcatat tataaatata aaaactttt tggagggacc tataagaaat	180
aattgaggaa taattaataa taagttgccc tcctttttt tctcttctcc ccaccctaaa	240
aataactcctg ggggggggag ggagagaatg tatgttagtgg ggagggtgta agttaataat	300
agacttaaat agagttatat aaaataacat aaatatgctt aaaataata ataataat	360
taacagatag aagccaaagg gtcaggcgct ttcttggga gaaagagtta gttagttcga	420
atctatccta tctga	435

<210> 65

<211> 299

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 65	
ttttgggtc gaggtgccgt aaagcactaa atcggAACCC taaagggagc ccccgattta	60
gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga aggaaagaaa gcgaaaggag	120
cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgttaaccacc acaccgccc	180
cgcttaatgc gccgctacag ggcgcgtcag gtggcacttt tcggggaaat gtgcgcggaa	240
cccctatttgc ttatTTTC taaatacatt caaatatgtt tccgctcatg agacaataa	299

<210> 66

<211> 153

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 66	
ctccactgtt acatttccca ctgtcctttt cccatcttc attttacaat gagcaagttt	60
cagaaaaaaa aatacaaatg ggataagtgc aaaacattcc atgtatctgt agcttccat	120
gttattcctc tctccagagt caggctctg tgt	153

<210> 67

p779.ST25

<211> 231

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 67
aattcaatag atgatgattt aacttcattt aatgagaaga tttcattttaga ttcaacaaaa 60
tctggagatt ttgcataaac aactgattt aatattagctt tattttctaa tccattaact 120
aattgatcat acataatata gatgaataag aataatgaaa ctagtgcaat aattgatcca 180
attgatgcta cataatttca accagcaaag gcatcagggt agtcaggaat t 231

<210> 68

<211> 52

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 68
ctcgtaaaaaa cgagcatgag ctgcgtcagg tcagccgtgg atatcggtgc gg 52

<210> 69

<211> 116

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 69
ctatctgcac gtgccaccgg aggtgctgtg ggagcgactg cggcacgatc gccatcgccc 60
gctgctgcag gtgccgcagc cgaggcagcg cattttcgaa ctctacgccc agcgcg 116

<210> 70

<211> 268

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 70
ccggccccttt gttgcgggcg gtgccatca ggccgcagcga gttgatctcg cgcagccgg 60
cctgggcata attgagcaaa tcgtactcgt gcgcggcgat gcgccttcgg ccgatcgaaat 120
tgacgtaatc gatgcggcg ccgagcccga tcgcctcgac gatcggcggc gtgcccggc 180
cgaacttgcg cggcgggtcg ccataggtga cccagtcctt ggcaacttca cggatcattt 240
cgccgcccgc gttgaacggc cgcatcgc 268

p779.ST25

<210> 71

<211> 869

<212> DNA

<213> *Zygosaccharomyces bailii*

<400> 71	60
cacacagaaa cagctatgac catgatacgc caagcttaat acgactca	ct ataggaaagc
tcggtaccac gcatgctgca gacgcgttac gtatcggtac cagaattcgt	gatattctat
tgggtatgtc ccctgattcg acggcgtaaa ttgcgtgaat ctgtgtttgg	cgctaattgac
cgcttttgg aattatgtgc tatgcctctg ccattggtat caacagctga	aatatttgg
gaagatcgaa tatcttctat tgtttctgag ggtatccccg aagctatggc	gaaagaaagg
atctcttctc gtacttggat cggtacgaga agcaatagac gcacaatgca	ttgacgcattc
ttgttgatac cgggtaatgt gagtcttctg gggtctgtta tttagttaa	tatgtcgtcc
acctctgttc tcgtatccat tttgcgagta gcccgcata cagcacgtcc	aatacaggag
aggccattta gcttcaggtg cagagaagac acagcatggt gctcaccttc	gagtgtctca
atagatgatt gagttgactg ggcttccgtg aaagggcctt tcgagagatc	ttcagaaata
aaccagggtt gcgcttcatt agtaggtgtt cctggaggac tattgtcgct	atctgctgga
ctactgctac caagtagtga agggggattt ctaaggctt cactctgttc	tgacactatt
ataacattgc caaggccaat ttgaaagggtt tcgcgtatat gagtaaagag	ctcggtgccc
ttccagttgg aatcaagccg ttcaagcaga tcgagagcat aatcagagtc	cacatttccg
cacgaagag agaactctga gttcattct	869

<210> 72

<211> 1425

<212> DNA

<213> *Zygosaccharomyces bailii*

<220>

<221> CDS

<222> (1)..(1425)

<223>

<400> 72	48
atg tcc gag ttt agc gag ctt gtc aga att ctc cca tta gac cag gtt	
Met Ser Glu Phe Ser Glu Leu Val Arg Ile Leu Pro Leu Asp Gln Val	
1 5 10 15	

p779.ST25

gca gaa ata aag cgt att ttg agt cgc ggc gac cct ata cct tta caa Ala Glu Ile Lys Arg Ile Leu Ser Arg Gly Asp Pro Ile Pro Leu Gln 20 25 30	96
agg tta gct tct cta cta act atg gtg atc cta acg gtc aac atg tca Arg Leu Ala Ser Leu Leu Thr Met Val Ile Leu Thr Val Asn Met Ser 35 40 45	144
aaa aag agg aag agc tct cca atc aag ctt agc acc ttt act aaa tat Lys Lys Arg Lys Ser Ser Pro Ile Lys Leu Ser Thr Phe Thr Lys Tyr 50 55 60	192
cgt aga aat gtt gcg aag tca ttg tat tat gat atg tca agc aag aca Arg Arg Asn Val Ala Lys Ser Leu Tyr Tyr Asp Met Ser Ser Lys Thr 65 70 75 80	240
gta ttc ttc gaa tac cat ctc aaa aat aca caa gat cta cag gag ggc Val Phe Phe Glu Tyr His Leu Lys Asn Thr Gln Asp Leu Gln Glu Gly 85 90 95	288
ctc gag caa gcc att gcg ccc tac aat ttc gtg gta aag gtg cac aag Leu Glu Gln Ala Ile Ala Pro Tyr Asn Phe Val Val Lys Val His Lys 100 105 110	336
aag cca att gat tgg cag aaa cag ctc tca agc gtg cat gag agg aaa Lys Pro Ile Asp Trp Gln Lys Gln Leu Ser Ser Val His Glu Arg Lys 115 120 125	384
gcg ggc cac aga agc att ctc agc aac aat gtt ggc gcc gag atc tct Ala Gly His Arg Ser Ile Leu Ser Asn Asn Val Gly Ala Glu Ile Ser 130 135 140	432
aaa ctg gct gag acg aaa gat tct act tgg agt ttt atc gag aga aca Lys Leu Ala Glu Thr Lys Asp Ser Thr Trp Ser Phe Ile Glu Arg Thr 145 150 155 160	480
atg gat ctg ata gaa gcc cgc acc cgc cag ccc acg aca aga gtt gcg Met Asp Leu Ile Glu Ala Arg Thr Arg Gln Pro Thr Thr Arg Val Ala 165 170 175	528
tat agg ttt ctg ctt caa ctc aca ttc atg aac tgc tgt agg gct aat Tyr Arg Phe Leu Leu Gln Leu Thr Phe Met Asn Cys Cys Arg Ala Asn 180 185 190	576
gat ttg aaa aac gcc gac ccc agc act ttt caa atc atc gca gat cct Asp Leu Lys Asn Ala Asp Pro Ser Thr Phe Gln Ile Ile Ala Asp Pro 195 200 205	624
cac ctt ggt cgt ata ttg cgg gcc ttt gtt cca gag aca aag act agc His Leu Gly Arg Ile Leu Arg Ala Phe Val Pro Glu Thr Lys Thr Ser 210 215 220	672
att gaa agg ttt atc tat ttt ttc cca tgt aag gga cga tgc gat ccg Ile Glu Arg Phe Ile Tyr Phe Phe Pro Cys Lys Gly Arg Cys Asp Pro 225 230 235 240	720
ctt ttg gct cta gat tcc tat ctc ctg tgg gtt ggc cca gtg ccc aaa Leu Leu Ala Leu Asp Ser Tyr Leu Leu Trp Val Gly Pro Val Pro Lys 245 250 255	768
act cag act acc gat gaa gag act caa tat gat tac cag ctt ctt caa Thr Gln Thr Thr Asp Glu Glu Thr Gln Tyr Asp Tyr Gln Leu Leu Gln 260 265 270	816
gat act ctc ttg att tcg tac gac agg ttt atc gcc aaa gaa tca aag Asp Thr Leu Leu Ile Ser Tyr Asp Arg Phe Ile Ala Lys Glu Ser Lys 275 280 285	864

p779.ST25

gaa aat att ttc aaa ata cct aat ggg ccc aaa gct cat ttg ggg cg	912
Glu Asn Ile Phe Lys Ile Pro Asn Gly Pro Lys Ala His Leu Gly Arg	
290 295 300	
cat cta atg gca tca tac ctt gga aac aac agt ctc aag agc gag gcc	960
His Leu Met Ala Ser Tyr Leu Gly Asn Asn Ser Leu Lys Ser Glu Ala	
305 310 315 320	
aca ctc tac ggc aac tgg tct gtg gaa agg caa gag ggc gtc agc aaa	1008
Thr Leu Tyr Gly Asn Trp Ser Val Glu Arg Gln Glu Gly Val Ser Lys	
325 330 335	
atg gct gac agc cga tac atg cac acg gtt aaa aaa agt cca cct tca	1056
Met Ala Asp Ser Arg Tyr Met His Thr Val Lys Lys Ser Pro Pro Ser	
340 345 350	
tat cta ttt gca ttt tta tcc ggc tac tac aaa aag tcc aac caa ggc	1104
Tyr Leu Phe Ala Phe Leu Ser Gly Tyr Tyr Lys Lys Ser Asn Gln Gly	
355 360 365	
gag tac gtg ctg gct gaa aca ctg tat aat ccc ctg gat tac gac aaa	1152
Glu Tyr Val Leu Ala Glu Thr Leu Tyr Asn Pro Leu Asp Tyr Asp Lys	
370 375 380	
aca ctt cca ata aca acg aac gag aaa ttg atc tgt cgg cgg tac ggg	1200
Thr Leu Pro Ile Thr Asn Glu Lys Leu Ile Cys Arg Arg Tyr Gly	
385 390 395 400	
aaa aat gcg aaa gtg ata cca aaa gac gca ctg ctg tat ctc tac acg	1248
Lys Asn Ala Lys Val Ile Pro Lys Asp Ala Leu Leu Tyr Leu Tyr Thr	
405 410 415	
tat gcg cag cag aag cga aaa caa ttg gcc gat ccc aat gag caa aat	1296
Tyr Ala Gln Gln Lys Arg Lys Gln Leu Ala Asp Pro Asn Glu Gln Asn	
420 425 430	
agg cta ttc agt agt gaa tca cca gcg cat ccc ttc tta act cct caa	1344
Arg Leu Phe Ser Ser Glu Ser Pro Ala His Pro Phe Leu Thr Pro Gln	
435 440 445	
tcg aca ggc tca tcg aca ccc ttg acc tgg act gct cca aag aca ctc	1392
Ser Thr Gly Ser Ser Thr Pro Leu Thr Trp Thr Ala Pro Lys Thr Leu	
450 455 460	
tcc act ggt cta atg aca cct gga gaa gag tag	1425
Ser Thr Gly Leu Met Thr Pro Gly Glu Glu	
465 470	

<210> 73

<211> 474

<212> PRT

<213> Zygosaccharomyces bailii

<400> 73

Met Ser Glu Phe Ser Glu Leu Val Arg Ile Leu Pro Leu Asp Gln Val	
1 5 10 15	

Ala Glu Ile Lys Arg Ile Leu Ser Arg Gly Asp Pro Ile Pro Leu Gln	
20 25 30	

p779.ST25

Arg Leu Ala Ser Leu Leu Thr Met Val Ile Leu Thr Val Asn Met Ser
35 40 45

Lys Lys Arg Lys Ser Ser Pro Ile Lys Leu Ser Thr Phe Thr Lys Tyr
50 55 60

Arg Arg Asn Val Ala Lys Ser Leu Tyr Tyr Asp Met Ser Ser Lys Thr
65 70 75 80

Val Phe Phe Glu Tyr His Leu Lys Asn Thr Gln Asp Leu Gln Glu Gly
85 90 95

Leu Glu Gln Ala Ile Ala Pro Tyr Asn Phe Val Val Lys Val His Lys
100 105 110

Lys Pro Ile Asp Trp Gln Lys Gln Leu Ser Ser Val His Glu Arg Lys
115 120 125

Ala Gly His Arg Ser Ile Leu Ser Asn Asn Val Gly Ala Glu Ile Ser
130 135 140

Lys Leu Ala Glu Thr Lys Asp Ser Thr Trp Ser Phe Ile Glu Arg Thr
145 150 155 160

Met Asp Leu Ile Glu Ala Arg Thr Arg Gln Pro Thr Thr Arg Val Ala
165 170 175

Tyr Arg Phe Leu Leu Gln Leu Thr Phe Met Asn Cys Cys Arg Ala Asn
180 185 190

Asp Leu Lys Asn Ala Asp Pro Ser Thr Phe Gln Ile Ile Ala Asp Pro
195 200 205

His Leu Gly Arg Ile Leu Arg Ala Phe Val Pro Glu Thr Lys Thr Ser
210 215 220

Ile Glu Arg Phe Ile Tyr Phe Phe Pro Cys Lys Gly Arg Cys Asp Pro
225 230 235 240

Leu Leu Ala Leu Asp Ser Tyr Leu Leu Trp Val Gly Pro Val Pro Lys
245 250 255

Thr Gln Thr Thr Asp Glu Glu Thr Gln Tyr Asp Tyr Gln Leu Leu Gln
260 265 270

Asp Thr Leu Leu Ile Ser Tyr Asp Arg Phe Ile Ala Lys Glu Ser Lys
275 280 285

Glu Asn Ile Phe Lys Ile Pro Asn Gly Pro Lys Ala His Leu Gly Arg
290 295 300

p779.ST25

His Leu Met Ala Ser Tyr Leu Gly Asn Asn Ser Leu Lys Ser Glu Ala
 305 310 315 320

Thr Leu Tyr Gly Asn Trp Ser Val Glu Arg Gln Glu Gly Val Ser Lys
 325 330 335

Met Ala Asp Ser Arg Tyr Met His Thr Val Lys Lys Ser Pro Pro Ser
 340 345 350

Tyr Leu Phe Ala Phe Leu Ser Gly Tyr Tyr Lys Lys Ser Asn Gln Gly
 355 360 365

Glu Tyr Val Leu Ala Glu Thr Leu Tyr Asn Pro Leu Asp Tyr Asp Lys
 370 375 380

Thr Leu Pro Ile Thr Thr Asn Glu Lys Leu Ile Cys Arg Arg Tyr Gly
 385 390 395 400

Lys Asn Ala Lys Val Ile Pro Lys Asp Ala Leu Leu Tyr Leu Tyr Thr
 405 410 415

Tyr Ala Gln Gln Lys Arg Lys Gln Leu Ala Asp Pro Asn Glu Gln Asn
 420 425 430

Arg Leu Phe Ser Ser Glu Ser Pro Ala His Pro Phe Leu Thr Pro Gln
 435 440 445

Ser Thr Gly Ser Ser Thr Pro Leu Thr Trp Thr Ala Pro Lys Thr Leu
 450 455 460

Ser Thr Gly Leu Met Thr Pro Gly Glu Glu
 465 470

<210> 74

<211> 1074

<212> DNA

<213> Zygosaccharomyces bailii

<220>

<221> CDS

<222> (1)..(1074)

<223>

<400> 74
 atg ttc tcc agg gaa gag gtt agg gcc tcc aaa ccc act aaa gag atg

48

p779.ST25																
Met	Phe	Ser	Arg	Glu	Glu	Val	Arg	Ala	Ser	Arg	Pro	Thr	Lys	Glu	Met	
1				5			10						15			
aag	atg	atc	ttt	gat	gtg	ctt	atg	aca	ttt	cct	tac	ttc	gcg	gta	cat	96
Lys	Met	Ile	Phe	Asp	Val	Leu	Met	Thr	Phe	Pro	Tyr	Phe	Ala	Val	His	
		20					25						30			
gtt	cct	tcc	aag	aat	ata	ctt	atc	aca	cca	aaa	ggc	aca	gtt	gag	ata	144
Val	Pro	Ser	Lys	Asn	Ile	Leu	Ile	Thr	Pro	Lys	Gly	Thr	Val	Glu	Ile	
		35				40				45						
cct	gaa	aac	tat	caa	aat	tat	ccc	ata	ttg	gcc	atc	ttc	tac	gtc	aaa	192
Pro	Glu	Asn	Tyr	Gln	Asn	Tyr	Pro	Ile	Leu	Ala	Ile	Phe	Tyr	Val	Lys	
		50				55			60							
tat	tta	atg	aag	aaa	aat	ccg	tac	gat	ctt	ctt	cca	agc	acc	gtg	aac	240
Tyr	Leu	Met	Lys	Lys	Asn	Pro	Tyr	Asp	Leu	Leu	Pro	Ser	Thr	Val	Asn	
		65				70			75					80		
tgg	ccg	gaa	ccc	tat	gta	gtg	gtg	aat	acc	atc	act	aag	cgt	ttc	cag	288
Trp	Pro	Glu	Pro	Tyr	Val	Val	Val	Asn	Thr	Ile	Thr	Lys	Arg	Phe	Gln	
				85			90					95				
gac	cat	aaa	cta	ttt	gca	aac	aaa	aat	gct	gat	gtc	tac	gtt	gaa	aga	336
Asp	His	Lys	Leu	Phe	Ala	Asn	Lys	Asn	Ala	Asp	Val	Tyr	Val	Glu	Arg	
		100				105						110				
ctt	caa	aat	gca	att	gcc	tcg	ggt	att	aag	att	cct	gag	tct	aag	aag	384
Leu	Gln	Asn	Ala	Ile	Ala	Ser	Gly	Ile	Lys	Ile	Pro	Glu	Ser	Lys	Lys	
		115				120					125					
aat	gaa	cga	tta	ggg	cag	cca	aaa	aag	acg	aaa	aat	gtt	aca	aaa	gag	432
Asn	Glu	Arg	Leu	Gly	Gln	Pro	Lys	Lys	Thr	Lys	Asn	Val	Thr	Lys	Glu	
		130				135			140							
att	gag	gag	acc	ttt	att	gat	gcc	act	aat	gcg	aga	aaa	gaa	ttg	gat	480
Ile	Glu	Glu	Thr	Phe	Ile	Asp	Ala	Thr	Asn	Ala	Arg	Lys	Glu	Leu	Asp	
		145				150				155				160		
gag	tac	ttc	aga	aaa	ctt	cag	gat	ggt	aca	tta	acc	gga	gat	ttg	gag	528
Glu	Tyr	Phe	Arg	Lys	Leu	Gln	Asp	Gly	Thr	Leu	Thr	Gly	Asp	Leu	Glu	
				165			170					175				
ggt	ggc	ttg	tgc	aag	gtc	aaa	acg	ctc	ata	tcg	tgt	aaa	gct	ttg	ttc	576
Gly	Gly	Leu	Cys	Lys	Val	Lys	Thr	Ile	Ser	Cys	Lys	Ala	Leu	Phe		
		180				185				190						
gga	gga	cac	acc	caa	gaa	ctc	cag	ttt	atg	gcc	acc	aat	gtt	cgt	aaa	624
Gly	Gly	His	Thr	Gln	Glu	Leu	Gln	Phe	Met	Ala	Thr	Asn	Val	Arg	Lys	
		195				200					205					
gtc	tgg	ata	ggg	gag	ata	gtg	tgc	ggc	atg	gtt	tcc	aat	aaa	aat	gca	672
Val	Trp	Ile	Gly	Glu	Ile	Val	Cys	Gly	Met	Val	Ser	Asn	Lys	Asn	Ala	
		210				215				220						
att	gac	gat	aat	gat	ctc	gag	gaa	gaa	gag	cgt	aat	gca	tcg	ggc	gaa	720
Ile	Asp	Asp	Asn	Asp	Leu	Glu	Glu	Glu	Arg	Asn	Ala	Ser	Gly	Glu		
		225				230			235					240		
caa	act	acg	aca	gcc	cga	gag	gaa	tca	gag	gct	ctg	gat	acc	aca	tcc	768
Gln	Thr	Thr	Thr	Ala	Arg	Glu	Glu	Ser	Glu	Ala	Leu	Asp	Thr	Thr	Ser	
				245			250					255				
aat	gtt	ttg	gac	gct	ctg	aat	act	caa	att	aat	gcc	ata	gaa	acg	gag	816
Asn	Gly	Leu	Asp	Ala	Leu	Asn	Thr	Gln	Ile	Asn	Ala	Ile	Glu	Thr	Glu	
		260				265				270						
gaa	tca	ttt	tgg	gaa	gct	atc	agg	gcg	ctc	cat	aat	gag	cta	cgc	acc	864

p779.ST25

Glu Ser Phe Trp Glu Ala Ile Arg Ala	Leu His Asn Glu Leu Arg Thr		
275	280	285	
tct cca aca cag tta gaa gag tgc agg aaa gca gtt ttt tta ctg		912	
Ser Pro Thr Gln Leu Glu Glu Cys Arg Lys Ala Ala Val Phe Leu Leu			
290	295	300	
ggc cat aaa aaa ata ctc caa aca ttt aca aag caa aag gat act gcc		960	
Gly His Lys Lys Ile Leu Gln Thr Phe Thr Lys Gln Lys Asp Thr Ala			
305	310	315	320
cgc gct ctt ttt tat ata aat ctc aaa gag tgt ctg gga acc agc tgg		1008	
Arg Ala Leu Phe Tyr Ile Asn Leu Lys Glu Cys Leu Gly Thr Ser Trp			
325	330	335	
aat tta gaa tat aca gag gca tca gat gca aga aaa atg gca att aaa		1056	
Asn Leu Glu Tyr Thr Glu Ala Ser Asp Ala Arg Lys Met Ala Ile Lys			
340	345	350	
ggt gag ctt caa aat taa		1074	
Gly Glu Leu Gln Asn			
355			

<210> 75

<211> 357

<212> PRT

<213> Zygosaccharomyces bailii

<400> 75

Met Phe Ser Arg Glu Glu Val Arg Ala Ser Arg Pro Thr Lys Glu Met			
1	5	10	15

Lys Met Ile Phe Asp Val Leu Met Thr Phe Pro Tyr Phe Ala Val His		
20	25	30

Val Pro Ser Lys Asn Ile Leu Ile Thr Pro Lys Gly Thr Val Glu Ile		
35	40	45

Pro Glu Asn Tyr Gln Asn Tyr Pro Ile Leu Ala Ile Phe Tyr Val Lys		
50	55	60

Tyr Leu Met Lys Lys Asn Pro Tyr Asp Leu Leu Pro Ser Thr Val Asn			
65	70	75	80

Trp Pro Glu Pro Tyr Val Val Asn Thr Ile Thr Lys Arg Phe Gln		
85	90	95

Asp His Lys Leu Phe Ala Asn Lys Asn Ala Asp Val Tyr Val Glu Arg		
100	105	110

Leu Gln Asn Ala Ile Ala Ser Gly Ile Lys Ile Pro Glu Ser Lys Lys		
115	120	125

p779.ST25

Asn	Glu	Arg	Leu	Gly	Gln	Pro	Lys	Lys	Thr	Lys	Asn	Val	Thr	Lys	Glu
130					135						140				
Ile	Glu	Glu	Thr	Phe	Ile	Asp	Ala	Thr	Asn	Ala	Arg	Lys	Glu	Leu	Asp
145					150				155				160		
Glu	Tyr	Phe	Arg	Lys	Leu	Gln	Asp	Gly	Thr	Leu	Thr	Gly	Asp	Leu	Glu
				165				170				175			
Gly	Gly	Leu	Cys	Lys	Val	Lys	Thr	Leu	Ile	Ser	Cys	Lys	Ala	Leu	Phe
				180			185				190				
Gly	Gly	His	Thr	Gln	Glu	Leu	Gln	Phe	Met	Ala	Thr	Asn	Val	Arg	Lys
				195		200					205				
Val	Trp	Ile	Gly	Glu	Ile	Val	Cys	Gly	Met	Val	Ser	Asn	Lys	Asn	Ala
					215				220						
Ile	Asp	Asp	Asn	Asp	Leu	Glu	Glu	Glu	Arg	Asn	Ala	Ser	Gly	Glu	
					230			235					240		
Gln	Thr	Thr	Thr	Ala	Arg	Glu	Glu	Ser	Glu	Ala	Leu	Asp	Thr	Thr	Ser
				245				250				255			
Asn	Gly	Leu	Asp	Ala	Leu	Asn	Thr	Gln	Ile	Asn	Ala	Ile	Glu	Thr	Glu
				260			265					270			
Glu	Ser	Phe	Trp	Glu	Ala	Ile	Arg	Ala	Leu	His	Asn	Glu	Leu	Arg	Thr
					275		280				285				
Ser	Pro	Thr	Gln	Leu	Glu	Glu	Cys	Arg	Lys	Ala	Ala	Val	Phe	Leu	Leu
					295				300						
Gly	His	Lys	Lys	Ile	Leu	Gln	Thr	Phe	Thr	Lys	Gln	Lys	Asp	Thr	Ala
				305		310			315				320		
Arg	Ala	Leu	Phe	Tyr	Ile	Asn	Leu	Lys	Glu	Cys	Leu	Gly	Thr	Ser	Trp
				325				330				335			
Asn	Leu	Glu	Tyr	Thr	Glu	Ala	Ser	Asp	Ala	Arg	Lys	Met	Ala	Ile	Lys
				340			345				350				
Gly	Glu	Leu	Gln	Asn											
				355											

<210> 76

<211> 750

<212> DNA

<213> Zygosaccharomyces bailii

p779.ST25

<220>

<221> CDS

<222> (1)..(750)

<223>

p779.ST25

aat tcc aaa aag cg_g tca tta gc_g cca aca caa gat tca cg_c aat tta 720
Asn Ser Lys Lys Arg Ser Leu Ala Pro Thr Gln Asp Ser Arg Asn Leu
225 230 235 240

cgc cgt cga atc agg gga cat acc caa tag
Arg Arg Arg Ile Arg Gly His Thr Gln
245

<210> 77

<211> 249

<212> PRT

<213> *Zygosaccharomyces bailii*

<400> 77

Met Asn Ser Glu Phe Ser Leu Ala Tyr Gly Asn Val Asp Ser Asp Tyr
1 5 10 15

Ala Leu Asp Leu Leu Glu Arg Leu Asp Ser Asn Trp Lys Gly Thr Glu
20 25 30

Leu Phe Thr His Ile Arg Glu Thr Phe Gln Ile Gly Leu Gly Asn Val
35 40 45

Ile Ile Val Ser Glu Gln Ser Glu Ser Leu Arg Ile Pro Pro Ser Leu
50 55 60

Leu Gly Ser Ser Ser Pro Ala Asp Ser Asp Asn Ser Pro Pro Gly Thr
65 70 75 80

Pro Thr Asn Glu Ala Gln Pro Trp Phe Ile Ser Glu Asp Leu Ser Lys
85 90 95

Gly Pro Phe Thr Glu Ala Gln Ser Thr Gln Ser Ser Ile Glu Thr Leu
100 105 110

Glu Gly Glu His His Ala Val Ser Ser Leu His Leu Lys Leu Asn Gly
115 120 125

Leu Ser Cys Ile Gly Arg Ala Val Trp Arg Ala Thr Arg Lys Met Asp
130 135 140

Thr Arg Thr Glu Val Asp Asp Ile Leu Asn Ser Ile Thr Glu Pro Arg
145 150 155 160

Arg Leu Thr Leu Pro Gly Ile Asn Lys Met Arg Gln Cys Ile Val Arg
165 170 175

Leu Leu Leu Leu Val Pro Ile Gln Val Arg Glu Glu Ile Leu Ser Phe
180 185 190

p779.ST25

Ala Ile Ala Ser Gly Ile Pro Ser Glu Thr Ile Glu Asp Ile Arg Ser
 195 200 205

Ser Thr Asn Ile Ser Ala Val Asp Thr Asn Gly Arg Gly Ile Ala His
 210 215 220

Asn Ser Lys Lys Arg Ser Leu Ala Pro Thr Gln Asp Ser Arg Asn Leu
 225 230 235 240

Arg Arg Arg Ile Arg Gly His Thr Gln
 245

<210> 78

<211> 453

<212> DNA

<213> *Saccharomyces cerevisiae*

<220>

<221> promoter

<222> (1)..(450)

<223>

<220>

<221> misc_feature

<222> (451)..(453)

<223> start codon

<400> 78		
ctacttattc ctttcgagat tataatctagg aacccatcag gttgggtggaa gattaccgt	60	
tctaaagactt ttcatcgttcc tctatttgatg ttacacctgg acaccccttt tctggcatcc	120	
agtttttaat cttcagtggc atgtgagatt ctccgaaatt aattaaagca atcacacaat	180	
tctctcgat accacctcgg ttgaaaactga caggtgggtt gttacgcattt ctaatgc当地	240	
ggagcctata tacctttggc tcggctgctg taacagggaa tataaagggc agcataattt	300	
aggagtttag tgaacttgca acatttacta ttttcccttc ttacgtaaat atttttcttt	360	
ttaattctaa atcaatcttt ttcaatttt tgtttgatt ctttcttgc ttaaatctat	420	
aactacaaaa aacacataca taaactaaaa atg	453	

<210> 79

p779.ST25

<211> 499

<212> DNA

<213> Zygosaccharomyces bailii

<220>

<221> promoter

<222> (1)..(496)

<223>

<220>

<221> misc_feature

<222> (497)..(499)

<223> start codon

<400> 79		
ggatcgatt gcttccattc ttctttgtt attcggcgcg attcgaattc atgacatctt	60	
ttaaccgtcc gcactacatt actggctcaa gaaaggattg ataaatacta ccaaggaaca	120	
cgtgtatcca tttgatactg tgctggttac aagacacatg ctttacaagc acacttctat	180	
ctctctcgac tgaggcgaaa cgtcgagtgg tttgatataca aatgcatacg tgatatgcac	240	
cattatttt cccttttact tccgtcacgc cggggctcca cttttttggg ttccactttt	300	
cttacgaccc tcgacatcca ctaaacgaac aggaagtcaa agaacccttc gagtcacacg	360	
gtgcgtatgc gctgttaaca tatataaagg tcacctttcc ctgctcaaaa gagtcttagc	420	
aggctgttaa cttcactctc tatcgatcca tagaatctaa ctaacaagag actacatcg	480	
tataacaaat aacaaaatg	499	

<210> 80

<211> 27

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 80		
aagagactcc aacgtcgcgac acctgtac	27	

<210> 81

p779.ST25

<211> 32

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 81

agaggattag gaagacacaa attgcattgtt ga

32

<210> 82

<211> 29

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 82

atcgtattgc ttccattctt cttttgtta

29

<210> 83

<211> 29

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 83

tttgttattt gttataccga tgtagtctc

29

<210> 84

<211> 27

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 84

tagctactct tctccaggtg tcattag

27

p779.ST25

<210> 85
<211> 25
<212> DNA
<213> artificial sequence

<220>
<223> PCR primer
<400> 85
cctatgtccg agtttagcga gcttg 25

<210> 86
<211> 25
<212> DNA
<213> artificial sequence

<220>
<223> PCR primer
<400> 86
agaatgaact cagagttctc tcttg 25

<210> 87
<211> 22
<212> DNA
<213> artificial sequence

<220>
<223> PCR primer
<400> 87
attctattgg gtatgtcccc tg 22

<210> 88
<211> 30
<212> DNA
<213> artificial sequence

<220>

p779.ST25

<223> PCR primer

<400> 88
gttttaatt ttgaagctca ccttaattg 30

<210> 89

<211> 26

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 89
attatgttct ccagggaga ggttag 26

<210> 90

<211> 27

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 90
agaatcaatc atttagtgtg gcaggag 27

<210> 91

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 91
taaaaactgc ccgccatatt tcgtc 25

<210> 92

<211> 708
<212> DNA

<213> Zygosaccharomyces rouxii

p779.ST25

<400> 92
 ctgcagaaag ccctaagatg ctcctccgt tcacatgctc cgaaccctt gaaaaattct 60
 gtgcggcg ctagcacgta atgacccttg atgacaact ccaatggtat caccctactg 120
 tcctcccccc ctccccttt tttccttctt tctttccatc tatttctgat ctccctccct 180
 cagcagatgt cccgaaaggta acagctgcga tacggcagc cacttttga cgtctcgcaa 240
 caggatcacc ctgcacgacg gggcacaata ggattccgt tgacacgggtg ctgggtgtata 300
 gcccggagg gtggggtata aagggtaca tccttacccc cacgcaggcg ataaccgcga 360
 tcataacaact gtccctccctc tccgctctcg ccactagccg cccaaccatt gctaccgcaa 420
 tgacaccgtg tggtgatctc aagggaggat gtgtgggtgt gggacggaaac ttccacttt 480
 tcctcagtag gtgcgatgcc cccCACACCG agcttccact aacgtgtttc agcgggtgaa 540
 ggcaatggga tcgcagaatt atcgcagctt gttgtatataa aagggagaaa gatatatggaa 600
 taagagacat gttctacttc tttctctct ttcttttat cctatatcac cagaacaaat 660
 caagttcgca ttgattcata tcaaataaaa agtacatcac agataaaca 708

<210> 93

<211> 21
<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 93

TGCAGAAAGC CCTAAGATGC T 21

<210> 94

<211> 29
<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 94

TGTCTGTGAT GTACTTTTA TTTGATATG 29

<210> 95

<211> 25
<212> DNA

<213> artificial sequence

<220>

<223> PCR primer

<400> 95

ACGCAAGAGA GAACTCTGAG TTCAT 25